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Skeletal muscle atrophy occurs with disuse after musculoskeletal injury, and during 
periods of sustained energy deficit.  Manipulating dietary protein intake or supplementing with 
testosterone under muscle wasting conditions may protect muscle mass and/or function by 
increasing muscle protein synthesis, attenuating muscle protein breakdown, and enhancing 
myogenesis either directly or via upstream modulation of inflammatory signaling.  The 
protective effect of dietary protein was evaluated in Study 1.  Vastus lateralis muscle collected 
perioperatively from anterior cruciate ligament (ACL) reconstruction patients assigned to an 
optimal (OP: 2.0 g·kg-1·d-1, n =3) or adequate (AP: 1.0 g·kg-1·d-1, n =2) protein diet for two 
weeks prior to surgery was analyzed for intracellular markers of myogenesis, inflammation, and 
protein turnover.  Thigh circumference and strength were measured before surgery and 2, 4, and 
8 weeks postoperatively.  Testosterone-mediated intracellular signaling regulating muscle mass 
was determined in Study 2 before and after a 28-day, severe diet- and exercise-induced energy 
deficit with weekly supplementation of 200 mg of testosterone enanthate (TEST; n=10) or a 
placebo (PLA; n=10) at baseline, 60 minutes after a bout of cycle ergometry, and 6 hours post-
exercise.  A protein-containing meal was consumed following the second biopsy.   
Higher protein intake before surgery did not influence perioperative markers of 
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muscle ring finger 1 (MuRF1) was greater in AP versus OP individuals at the time of surgery.  
Postoperative thigh circumference at week 2, 4, and 8 relative to baseline was associated with 
perioperative gene expression of paired box 7 (Pax7), fibroblast growth factor-inducible 14 
(Fn14), and tumor necrosis factor-α-receptor (TNFα-R), respectively. Similarly, perioperative 
markers of inflammation and myogenesis were associated with quadriceps strength at 8 weeks 
post-surgery relative to pre-surgery measures.  Testosterone supplementation during energy 
deficit attenuated Fn14 gene expression and increased androgen receptor protein content at 
baseline, and upregulated expression of the myogenic regulatory factor MyoD and attenuated 
proteolytic gene expression after exercise and feeding.       
 
In total, findings from Study 1 and Study 2 indicate integration of intramuscular inflammation, 
dietary protein intake, and testosterone-mediated intracellular signaling in the regulation of 
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 Muscle atrophy occurs with reduced loading and neural activation of muscle after a 
musculoskeletal injury (i.e., disuse atrophy) (1, 2) and during energy deficit resulting from 
inadequate caloric intake (3).  Muscle mass is regulated by rates of muscle protein synthesis 
(MPS) and muscle protein breakdown (MPB) that fluctuate throughout the day in response 
feeding and fasting.  A persistent negative net balance (i.e., MPS < MPS) during disuse or energy 
deficit due to decreased MPS, increased MPB, or both, underlies the associated loss of lean mass 
(3, 4).  Muscle mass is also regulated by the repair and replacement of damaged fibers through 
myogenesis.  The myogenic response involves activation of normally quiescent muscle stem 
cells (i.e., satellite cells) to form new multinucleated myotubes that fuse with existing fibers (5).  
Upstream regulation of myogenesis involves transient increases in local inflammatory cytokine 
expression that promote the activation, proliferation, and differentiation of satellite cells (6, 7).  
If intramuscular inflammation persists chronically, however, regenerative capacity is diminished 
and muscle atrophy ensues (8, 9).  Interventions designed to modulate protein turnover and 
enhance myogenesis by attenuating excessive inflammatory signaling may preserve muscle mass 
under muscle wasting conditions.   
Manipulating the amount and quality of dietary protein is one possible strategy to protect 
muscle during disuse after musculoskeletal injury.  The proposed anti-inflammatory role of 
branched chain amino acids (BCAAs) (10), and the capacity of essential amino acid (EAA) 
supplementation to modulate satellite cell activity directly (11), suggests that manipulating 
dietary protein intake may enhance muscle regenerative capacity to promote recovery from 




protein ingestion to overcome disuse-induced deficits in postprandial MPS and protect muscle 
mass (12). 
Exogenous testosterone administration has been shown to increase rates of fasted-state 
MPS (13, 14), enhance satellite cell activity (15), and attenuate inflammatory signaling (16).  
Given that the loss of lean body mass with severe energy deficit generally occurs with a 
concomitant suppression of the hypothalamic-pituitary-gonadal axis (17), testosterone 
supplementation may represent one strategy to modulate MPS, myogenesis, and inflammation to 
attenuate muscle losses under these conditions.  However, the molecular impacts of exogenous 
testosterone administration during severe exercise- and diet-induced energy deficit remain 
unexplored.    
 
This dissertation therefore aims to:  
1.) Determine whether varied protein intakes (1.0 vs. 2.0 g·kg-1·d-1) for 2 weeks prior to 
anterior cruciate ligament (ACL) reconstruction surgery modulates perioperative 
markers of intramuscular inflammation and myogenesis; 
2.) Associate muscle regeneration capacity at the time of ACL surgery (i.e., inflammatory 
and myogenic signaling) with postoperative recovery outcomes;  
3.) Determine the effects of increasing postoperative dietary protein intake  
(~2.0 g·kg-1·d-1) on preserving muscle mass and function outcomes after ACL 
reconstruction; and  
4.) Characterize intracellular signaling and gene expression mediating the hypertrophic 
effects of supplemental testosterone during a severe diet- and exercise-induced energy 





1. Wall BT, Dirks ML, Snijders T, Senden JM, Dolmans J, van Loon LJ. Substantial skeletal 
muscle loss occurs during only 5 days of disuse. Acta Physiol (Oxf). 2014;210(3):600-611. 
 
2. Thomas AC, Wojtys EM, Brandon C, Palmieri-Smith RM. Muscle atrophy contributes to 
quadriceps weakness after anterior cruciate ligament reconstruction. J Sci Med Sport. 
2016;19(1):7-11. 
 
3. Carbone JW, McClung JP, Pasiakos SM. Skeletal muscle responses to negative energy 
balance: effects of dietary protein. Adv Nutr. 2012;3(2):119-126. 
 
4. Phillips SM, Glover EI, Rennie MJ. Alterations of protein turnover underlying disuse 
atrophy in human skeletal muscle. J Appl Physiol (1985). 2009;107(3):645-654. 
 
5. Snijders T, Nederveen JP, McKay BR, et al. Satellite cells in human skeletal muscle 
plasticity. Front Physiol. 2015;6:283. 
 
6. Hoene M, Runge H, Haring HU, Schleicher ED, Weigert C. Interleukin-6 promotes 
myogenic differentiation of mouse skeletal muscle cells: role of the STAT3 pathway. Am J 
Physiol Cell Physiol. 2013;304(2):C128-136. 
 
7. Enwere EK, Holbrook J, Lejmi-Mrad R, et al. TWEAK and cIAP1 regulate myoblast 
fusion through the noncanonical NF-kappaB signaling pathway. Sci Signal. 
2012;5(246):ra75. 
 
8. Dogra C, Changotra H, Mohan S, Kumar A. Tumor necrosis factor-like weak inducer of 
apoptosis inhibits skeletal myogenesis through sustained activation of nuclear factor-
kappaB and degradation of MyoD protein. J Biol Chem. 2006;281(15):10327-10336. 
 
9. Dogra C, Changotra H, Wedhas N, Qin X, Wergedal JE, Kumar A. TNF-related weak 
inducer of apoptosis (TWEAK) is a potent skeletal muscle-wasting cytokine. FASEB J. 
2007;21(8):1857-1869. 
 
10. Nicastro H, da Luz CR, Chaves DF, et al. Does Branched-Chain Amino Acids 
Supplementation Modulate Skeletal Muscle Remodeling through Inflammation 
Modulation? Possible Mechanisms of Action. J Nutr Metab. 2012;2012:136937. 
 
11. Farup J, Rahbek SK, Knudsen IS, de Paoli F, Mackey AL, Vissing K. Whey protein 
supplementation accelerates satellite cell proliferation during recovery from eccentric 
exercise. Amino Acids. 2014;46(11):2503-2516. 
 
12. Wall BT, Morton JP, van Loon LJ. Strategies to maintain skeletal muscle mass in the 






13. Ferrando AA, Tipton KD, Doyle D, Phillips SM, Cortiella J, Wolfe RR. Testosterone 
injection stimulates net protein synthesis but not tissue amino acid transport. Am J Physiol. 
1998;275(5):E864-871. 
 
14. Urban RJ, Bodenburg YH, Gilkison C, et al. Testosterone administration to elderly men 
increases skeletal muscle strength and protein synthesis. Am J Physiol. 1995;269(5 Pt 
1):E820-826. 
 
15. Sinha-Hikim I, Cornford M, Gaytan H, Lee ML, Bhasin S. Effects of testosterone 
supplementation on skeletal muscle fiber hypertrophy and satellite cells in community-
dwelling older men. J Clin Endocrinol Metab. 2006;91(8):3024-3033. 
 
16. Urban RJ, Dillon EL, Choudhary S, et al. Translational studies in older men using 
testosterone to treat sarcopenia. Trans Am Clin Climatol Assoc. 2014;125:27-42; 
discussion 42-24. 
 
17. Henning PC, Scofield DE, Spiering BA, et al. Recovery of endocrine and inflammatory 








Review of Literature 
a. Inflammation and myogenesis in the recovery from skeletal muscle injury  
Skeletal muscle damage and a corresponding loss of function occurs as a result of strains, 
contusions, lacerations, ischemia, burns, and even strenuous exercise.  Musculoskeletal injuries 
requiring surgical interventions can also lead to extensive muscle damage.  Damage to the 
muscle surrounding the hip or knee, for example, is inevitable during total hip or total knee 
arthroplasty (THA or TKA) procedures, respectively (1).  Using a tourniquet to maintain a 
bloodless field during surgery also causes muscle trauma through the associated ischemia and 
reperfusion injury (2).  Skeletal muscle has the intrinsic capacity to regenerate and repair itself 
following these types of injuries through myogenesis.  This myogenic response involves the 
activation of muscle-resident stem cells (i.e., satellite cells) that ultimately regenerate and 
remodel the injured tissue.    
In addition to muscle tissue damage itself, the loss of limb function and mobility with 
skeletal muscle injury induces a rapid loss of muscle mass (i.e., disuse atrophy) and function 
given the unloading and reduced neural activation of muscle.  Rehabilitation begins gradually 
post-injury or post-operatively to attenuate these muscle losses and regain muscle mass, strength, 
and function in the injured limb.  Restoring muscle mass is mediated by a positive muscle 
protein balance (i.e., muscle protein synthesis > muscle protein breakdown).  Myogenesis also 
appears to be involved in restoring muscle mass as muscle fiber hypertrophy was compromised 
after 8 weeks of overloading in mouse muscle depleted of satellite cells (3).  Myogenesis is 




damaged muscle tissue, but to also add new nuclei to existing myofibers in support of muscle 
hypertrophy during rehabilitation (4). 
Myogenesis is a complex and highly regulated process involving the activation of 
normally quiescent satellite cells to reenter the cell cycle and generate myoblasts in response to 
exercise, damage, or other stimuli (5).  Myoblasts proliferate rapidly and differentiate by 
increasing expression of specific transcription factors (e.g. Pax7, Myf5, MyoD, myogenin, 
MRF4) (Fig 2.1).  Differentiated myoblasts then fuse with each other or existing myofibers to 
regenerate and repair damaged tissue.  Activation of fibro/adipogenic progenitor (FAP)-mediated 
remodeling of the connective tissue extracellular matrix (ECM) supports this myogenic response 
(6).  Revascularization and reinnervation of damaged muscle tissue through angiogenesis and 
neuromuscular junction formation, respectively, is also necessary to restore muscle function 
post-injury (7).        
 
     Figure 2.1.  Myogenic regulatory factor expression mediates the progression of myogenesis  
 
 
Regulation of the regenerative response is multifaceted and involves factors such as 
inflammatory cytokines, growth factors, immune cell infiltration, hypoxia and nutrient 




damage with the activation of the complement system.  Neutrophils and macrophages infiltrate 
the injured area as a result to clear cellular debris.  Inflammatory cytokines are then secreted by 
these immune cells and myofibers themselves, modifying the local microenvironment to promote 
satellite cell activation, proliferation, and differentiation (10).  
The release of inflammatory cytokines following muscle damage is a finely regulated 
response.  An early and continuous presence of several pro-inflammatory cytokines (e.g., TNFα, 
TWEAK) mediate early stages of muscle regeneration and repair (11, 12).  This local elevation 
in pro-inflammatory cytokine expression persists for only a short time.  A shift from pro- to anti-
inflammatory signaling (e.g., IL-13, IL-10, IL-4) within days of muscle injury represses the local 
inflammatory response and supports later phases of myogenesis (13, 14).  The regenerative 
response to muscle damage is therefore impaired with exceedingly high or chronic expression of 
pro-inflammatory cytokines.  Disrupting the switch from pro- to anti-inflammatory signaling has 
been shown to increase ECM deposition and favor muscle degeneration and fibrogenesis (15).  
Persistent pro-inflammatory cytokine signaling may also promote muscle wasting by blunting 
muscle protein synthesis and triggering muscle protein breakdown (16, 17).  While multiple 
cytokines are involved in regulating these processes, TWEAK, TNFα, IL-6 and their respective 
molecular pathways appear to be shared across conditions of both acute and chronic 
inflammation.    
 
b. Divergent roles of inflammation in the regulation of muscle mass 
Physiological and pathophysiological stress can trigger a muscle inflammatory response 
that promotes muscle growth or muscle loss, respectively.  Transiently elevated muscle 
inflammation after routine exercise, for example, is a normal physiological response that 




inducer of apoptosis (TWEAK) and its receptor fibroblast growth factor-inducible 14 (Fn14) 
constitute one signaling pathway involved in this response.  Levels of the TWEAK receptor 
Fn14 are generally low in healthy tissues and therefore the induction of Fn14 expression is tied 
to TWEAK/Fn14 pathway activity (18).  Fn14 mRNA has been shown to increase in animals 
after skeletal muscle tissue injury, denervation of skeletal muscle, and in response to growth 
factors such as PDGF and VEGF (19).  While literature examining the TWEAK-Fn14 axis in 
human skeletal muscle is limited, Raue and colleagues (20) were the first to observe increased 
intramuscular Fn14 gene expression in humans following exercise.  Skeletal muscle Fn14 
expression was induced after an acute resistance exercise bout in mixed muscle and in MHC IIa 
muscle fibers of young and old subjects (20).  Its induction also positively correlated with 
skeletal muscle growth (cross sectional area) and functional improvements (1- repetition 
maximum) over 12 weeks of training (20).  An Fn14 gene response in fast-twitch fibers has also 
been observed in highly trained college runners after tapered run training, a time when these 
muscle fibers increase in size (21).  Collectively, these findings highlight a growth-related 
physiological role for the TWEAK-Fn14 axis in human skeletal muscle.    
The pro-growth qualities of TWEAK/Fn14 signaling may explain the apparent benefit of 
heightened intramuscular inflammation during a period of muscle loss in a healthy population.  
Total body mass decreased by approximately 9% in a population of healthy males subjected to 
21 days of high altitude exposure and a simultaneous energy deficit achieved through dietary 
restriction and multiple bouts of aerobic-type exercise (22).  Approximately 43% of this loss in 
total body mass was attributed to a decrease in fat-free mass (22).  Markers of muscle 
inflammation (e.g. TWEAK, Fn14, TNF-α, and TNF-α -R) and myogenic regulatory factors (e.g. 




and LOW Fn14 expression revealed that those classified as HIGH lost significantly less fat-free 
mass and displayed increased myogenic regulatory factory gene expression versus those 
classified as LOW (22).  These findings suggest that a heightened muscle inflammatory response 
to chronic high altitude exposure, underfeeding and exercise may benefit muscle maintenance 
under these conditions by promoting muscle regeneration. 
In contrast, exceedingly high or chronic skeletal muscle inflammation may inhibit muscle 
regeneration and promote muscle wasting by blunting muscle protein synthesis and triggering 
muscle protein breakdown.  This is evident in several pathophysiological conditions of muscle 
wasting.  Burn injury, as an extreme example, leads to skeletal muscle breakdown throughout the 
body.  A marked increase in vastus lateralis mRNA expression of TWEAK-, tumor necrosis 
factor-α (TNFα)- and interleukin (IL)-6-family cytokines and receptors 5-days post burn injury 
suggests changes in inflammatory signaling may contribute to the observed atrophy (23).  
Elevated expression of TWEAK and TNFα receptors has similarly been observed in paralyzed 
muscle of men with chronic spinal cord injury, a condition that also presents with muscle atrophy 
and impaired regenerative capacity (24).     
i. Inflammation and myogenesis 
The opposing roles of inflammation observed in humans correspond with the 
concentration- and time-dependent regulation of myogenesis by several inflammatory cytokines 
in cell and animal models (Fig. 2.2).  TWEAK, for example, has emerged as a cytokine capable 
of modulating myogenesis.  Initial studies demonstrated that high concentrations of exogenous 
TWEAK (≥ 100 ng/mL) in cultured myoblasts enhanced proliferation but inhibited subsequent 
differentiation and myotube formation (11, 25).  The observed impairment in cell cycle exit and 




gene expression and protein levels of the myogenic regulatory factors MyoD and myogenin (11, 
25).  Activation of classical (canonical) nuclear factor-kB (NF-κB) signaling appears to mediate 
this response.  NF-κB proteins are a family of structurally similar transcription factors (p65, 
RelB, c-Rel, p105/p50, and p100/p52) that form either homodimers or heterodimers.  Classical 
signaling specifically involves the phosphorylation and degradation of an inhibitory protein 
(IκBα) and subsequent translocation of an activated p65/p50 heterodimer to the nucleus (26).  
Inhibiting p65/p50 activity reversed the inhibitory effect of soluble TWEAK (500 ng/mL) on 
differentiation and MyoD protein expression in cultured myoblasts (25), suggesting high 
concentrations of TWEAK limit normal myogenic progression through classical NF-κB activity.   
High concentrations of TWEAK enhancing proliferation and inhibiting differentiation 
through classical NF-κB signaling would be critical during early phases of muscle regeneration 
to promote rapid proliferation and adequate expansion of the myoblast population, while 
simultaneously avoiding premature differentiation (18).  In contrast, TWEAK present at low 
concentrations (10 ng/mL) in C2C12 myoblasts has been shown to promote later stages of 
myogenesis through the activation of alternative (noncanonical) NF-κB signaling (27). The 
alternative NF-κB signaling pathway involves the phosphorylation and partial proteasomal 
degradation of a p100 subunit to p52 to generate a p52/RelB heterodimer (26).  Translocation of 
the p52/RelB heterodimer to the nucleus and subsequent transcriptional activity promotes 
myogenesis by stimulating myoblast fusion into myotubes.  Exposing differentiating myoblasts 
to low concentrations of exogenous TWEAK (10 ng/mL) increased myoblast fusion and doubled 
myotube diameter when compared to untreated cells (27).   
The cytokine TNFα also regulates myogenesis. TNFα concentrations rise substantially at 




(28).  The early increase in TNFα expression functions as a chemoattractant signal that 
stimulates myogenic cell migration to the site of injury (29).  The initially high concentrations of 
TNFα also play a role in promoting proliferation (12) and inhibiting myogenic differentiation 
(30).  This occurs analogous to TWEAK through the activation of classical NF-κB signaling and 
downstream inhibition of MyoD mRNA and protein expression (30).  While high concentrations 
of recombinant TNFα (≥ 0.5 ng/mL) inhibit the progression of myogenesis, low concentrations 
of TNFα (0.05 ng/mL) have been shown to enhance differentiation in cultured myoblasts (31).  
This response appears to occur through downstream activation of p38 MAPK.  Levels of 
activated p38 MAPK and markers of differentiation were both diminished when TNFα was 
neutralized in C2C12 myoblast (31).  p38 MAPK activation and muscle regeneration were also 
impaired following cardiotoxin-injury of soleus muscle in TNFα receptor double knockout mice 
(p55-/-p75-/-) (32).   
The cytokine IL-6 is another major regulator of myogenesis.  IL-6 binding to its receptor 
activates the Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling 
cascade.  IL-6-dependent activation of STAT3 specifically was required for satellite cell 
proliferation in vitro (33).  IL-6 is also necessary for the complete differentiation of muscle cells.  
Primary muscle cells from IL-6-/- mice displayed a clear reduction in myotube formation 
indicative of decreased myoblast fusion (34).  This occurred independent of downstream STAT3 
activation, although the exact mediators of this effect are unknown.  How exceedingly high 
levels of IL-6 affect myogenesis is unclear, however, chronic overexpression of IL-6 has been 
shown to induce muscle wasting (16).   
In total, these findings specific to TWEAK, TNFα, and IL-6 indicate that high 




note, however, that the physiological relevance of these in vitro studies remains unclear as they 
generally involve acute exposure to very high concentrations of a single cytokine.  The 
involvement of multiple cytokines under physiological conditions and the varied concentrations 
of cytokines between plasma and muscle interstitium due to the presence of an endothelial 
barrier are possible confounding factors that must be considered.  Regardless, these findings 
collectively suggest that a transient increase in intramuscular pro-inflammatory signaling after 
injury is required for muscle regeneration and repair, while an excessive or persistent 




Figure 2.2.  Inflammation and myogenesis 
 
ii. Inflammation and muscle protein turnover 
Exceedingly high or chronic expression of pro-inflammatory cytokines following muscle 
injury impairs recovery by promoting muscle wasting (Fig. 2.3).  Differentiated C2C12 
myotubes incubated with soluble TWEAK (10 ng/mL), for example, display reduced mass and a 
loss of total protein content (17).  Mice subjected to chronic administration of soluble TWEAK 




compared to control mice (17).  This effect appears to involve multiple signaling pathways that 
promote protein catabolism and impair anabolic signaling.  Activation of NF-κB, for example, is 
involved in the TWEAK-induced degradation of cultured myotubes (17).  NF-κB signaling likely 
mediates this effect by up-regulating the ubiquitin proteasome system (UPS).  The UPS is largely 
responsible for the degradation of myofibrillar proteins through the enzymatic activity of the 
muscle-specific ubiquitin ligases muscle atrophy F-box (MAFbx/Atrogin-1) and muscle ring 
finger 1 (MuRF1).  NF-κB has been shown to regulate MuRF1 expression (35), which was 
increased along with MAFbx following TWEAK treatment of cultured myotubes (17).   
Inhibition of the phosphatidylinositol-3 kinase (PI3K)/Akt pathway may also contribute 
to the observed up-regulation of UPS activity in TWEAK-treated myotubes.  Active Akt 
phosphorylates and inhibits the forkhead box O (FoxO) transcription factor, preventing its 
translocation to the nucleus and induction of MAFbx and MuRF1 expression (36).  Exogenous 
TWEAK in cultured myotubes significantly decreased Akt and FOXO1a phosphorylation, 
suggesting increases in MAFbx and MuRF1 following TWEAK treatment are also due to Akt 
inhibition (17).  TWEAK-mediated inhibition of the PI3K/Akt is also consequential to anabolic 
signaling.  Akt facilitates translation initiation and muscle protein synthesis through the 
phosphorylation and activation of the mammalian target of rapamycin (mTOR) and subsequent 
activity of its downstream targets, p70S6K and 4E-BP1 (37). Active Akt also phosphorylates 
GSK-3β, reversing its inhibitory effect on the translation initiation factor eIF2B (38).  
Phosphorylation levels of GSK-3β, mTOR, and p70S6K were decreased following TWEAK 
treatment of cultured myotubes, indicating impaired anabolic signaling (17).  An imbalance 




Elevated levels of TNFα modulate muscle protein turnover and induce atrophy.  A dose-
dependent loss of total protein was noted in differentiated skeletal muscle myotubes following 
prolonged exposure to TNFα (1 – 6 ng/mL) (39).  TNFα appears to mediate this effect by 
activating NF-κB transcriptional activity (16) and inhibiting Akt (42), triggering downstream up-
regulation MAFbx and MuRF1 expression.  The up-regulation of MAFbx in C2C12 myoblasts 
following TNFα exposure also required intact p38 MAPK, indicating the TNFα/p38 MAPK 
signaling axis enhances downstream UPS activity and related muscle catabolism (41).  Increased 
TNFα concentrations have also been shown to limit muscle anabolism via the PI3K/Akt 
signaling pathway.  Upstream activation of PI3K/Akt signaling involves the binding of factors 
such as insulin-like growth factor 1 (IGF-1) or insulin to their receptors and the subsequent 
phosphorylation and activation of insulin receptor substrate 1 (IRS-1).  TNFα may exert its anti-
anabolic effect by downregulating IGF-1 synthesis or by direct interaction with IRS-1.  Addition 
of TNFα to cultured myotubes decreased IGF-1 mRNA expression by 50-80% (42).  TNFα has 
also been shown to stimulate serine residue phosphorylation of IRS-1, preventing its recruitment 
to the insulin/IGF-1 receptor (43).  In theory, this would ultimately suppress anabolic (i.e., 
mTOR, p70S6K) and promote catabolic (i.e., FOXO, MuRF1, MAFbx) signaling downstream of 
the IGF-1 receptor.   
The effects of heightened IL-6 expression on muscle anabolic and catabolic signaling 
pathways in vivo remain elusive.  Locally infusing soluble IL-6 in muscles of rats significantly 
decreased myofibrillar protein content compared to untreated contralateral muscle (16).  
Inhibiting STAT3 in C2C12 myoblasts reduced muscle atrophy downstream of IL-6, implicating 
the JAK/STAT3 pathway as a mediator of IL-6-induced muscle wasting (44).  The mechanisms 




may also result from a downregulation of anabolic signaling pathways.  An increase in IGF-1 
mRNA and decrease in downstream phosphorylation of p70S6K has been observed in IL-6-
infused muscles of rats (16).  These findings suggest that IL-6 disrupts growth factor-related 
intracellular signaling, resulting in a compensatory increase in IGF-1 production (16).   
  
 
Figure 2.3.  Inflammation and muscle protein turnover  
 
c. Variability in muscle inflammation susceptibility  
Heightened basal (pre-injury or pre-surgery) levels of intramuscular inflammation, an 
exaggerated inflammatory response to muscle damage, or both, would lead to exceedingly high 
levels of muscle inflammation post-injury that could impair myogenesis and promote atrophy.  
Interestingly, basal levels of inflammation and the sensitivity to inflammatory stimuli may not be 
uniform across all populations.  Merritt and colleagues (45) observed differences in basal muscle 
pro-inflammatory signaling independent of circulating cytokines between middle-aged adults 
(40.4 ± 1.1 yr, AGE40), older adults (61.2 ± 0.6 yr, AGE61), and elderly (75.5 ± 0.7 yr, AGE76) 




relative to AGE40 at baseline and following modest muscle damage induced with a resistance 
exercise protocol (45).  Myoblasts isolated from three young (28 ± 2 yr) versus three older (64 ± 
2 yr) individuals also displayed greater inflammatory signaling in the absence of a pro-
inflammatory stimulus, and had an exaggerated inflammatory response and reduced fusion 
capacity when treated with TNFα (45).  This heightened basal pro-inflammatory signaling and 
hypersensitivity to inflammatory stimuli in individuals of advanced age was defined as “muscle 
inflammation susceptibility”, or MuIS(+).  This MuIS(+) phenotype, along with cell-intrinsic 
defects in satellite cell self-renewal observed with aging (46), impair myogenesis as well as 
promote muscle atrophy following muscle injury.    
Follow-up work by Bamman et al. (47) described analyses identifying the MuIS(+) 
phenotype in certain adults across all ages, suggesting some individuals display elevated basal 
levels of muscle inflammation and an exaggerated or prolonged response to an inflammatory 
insult.  This apparent interindividual variability in heightened inflammation susceptibility 
suggests some individuals may be more prone to an exceedingly high inflammatory response to 
muscle injury that would be detrimental to recovery.  Bamman et al. (47) considered this 
hypothesis by evaluating MuIS status in patients undergoing total hip arthroplasty (THA) for 
end-stage osteoarthritis, since osteoarthritis-related damage in the hip leads to immune cell 
infiltration and heightened inflammatory cytokine expression in the synovial fluid, synovial 
membrane, cartilage, and the subchondral bone layer (48, 49).  In theory, evaluating MuIS status 
would ascertain the susceptibility of muscle surrounding the hip to the local inflammatory 
burden of the osteoarthritic joint (47).  
The MuIS(+) phenotype was identified in a population of THA patients based on the 




surrounding the diseased hip (47).  Levels of Fn14 are generally low in healthy tissues and 
therefore the induction of Fn14 expression in response to injury, stress, or exercise is tied to 
TWEAK/Fn14 pathway activity (18).  Dichotomization into MuIS(+)  and MuIS(-) individuals was 
done based on median Fn14 expression and revealed several key differences between groups.  
The MuIS(+) group (n=7) had a mean Fn14 gene expression that was five times higher than the 
MuIS(-) group (n=8) (47).  Individuals designated as MuIS(+) also exhibited heightened 
expression of all inflammatory genes evaluated (e.g., TNFα, IL-6, TWEAK) compared to non-
surgical controls, while only the up-regulation of the IL-6 receptor (IL-6R) was found in the 
MuIS(-) group (47).  Significantly lower muscle protein synthesis (i.e., fractional synthetic rate) 
was observed in muscle surrounding the diseased hip in the MuIS(+) versus MuIS(-) groups (47).  
The heightened inflammatory signaling and changes in muscle protein synthesis in the MuIS(+)  
versus MuIS(-) group would be expected to reduce myogenic activity and induce muscle atrophy.  
These findings collectively suggest that dichotomization of individuals based on Fn14 expression 
reveals a phenotype that would be detrimental to recovery from THA, though long-term 
investigations evaluating the recovery potential of MuIS(+) versus MuIS(-) THA patients are 
currently lacking.   
The possibility exists that these observations may not be unique to THA patients.  
Levinger and colleagues (50) observed heightened inflammatory cytokine expression in the 
vastus lateralis of patients undergoing total knee arthroplasty (TKA) for end-stage osteoarthritis.  
This observation is intriguing given the relative distance between the inflamed joint and 
surrounding musculature, and may be relevant to other orthopedic injuries and surgeries.  
Anterior cruciate ligament (ACL) injury and reconstruction, for example, has been associated 




on the findings in TKA patients, it is plausible that the local knee inflammation observed with 
ACL injury and reconstruction may similarly extend to the vastus lateralis.  A heightened 
susceptibility to a locally inflamed joint (e.g., knee, hip, or shoulder) following musculoskeletal 
injury may contribute to an excessive inflammatory response to surgical treatment that limits 
regeneration of damaged tissue and promotes atrophy in the postoperative period.  Whether this 
situation provides insight into a patient’s rehabilitative potential is not known.     
Potential problems with existing methods of determining MuIS status that currently limit 
its clinical application should be noted.  Dichotomization based on Fn14 expression, for 
example, results in groups of individuals (i.e., above versus below the cut-off point) that are 
considered equal although their individual prognosis may vary considerably.  Likewise, 
individuals close to, but on opposite sides of, the cut-off point are regarded as very different.  
Dichotomization based on the sample median also means that the exact value of the cut-off point 
could change considerably from sample to sample.  Finally, the clinical application of this tool in 
its current form has methodical limitations.  Collecting a muscle sample and evaluating gene 
expression is outside the scope of most clinical sites and laboratories. Nonetheless, potential 
benefits to determining MuIS status in orthopedic patient populations with specific regard for 
prognostic outcomes following surgical interventions warrants further investigations.    
 
d. Dietary protein intake and myogenesis  
The relationship between dietary protein intake and satellite cell-mediated muscle 
regeneration and remodeling is not fully understood.  Some insight is provided by in vitro studies 
evaluating the effect of amino acid availability on the myogenic response.  Adding branched 
chain amino acids (BCAAs) (52) or leucine alone (53) to culture medium of C2C12 myoblasts, 




cells similarly enhanced myotube formation and increased MyoD and myogenin expression (54), 
while the removal of leucine from culture media prevented differentiation of C2C12 myoblasts 
and primary satellite cells from mice (55).  Leucine supplementation has also been shown to 
modulate satellite cell dynamics in vivo.  Pereira and colleagues (56) provided leucine to young 
and old rats for 3 days before and 10 days after cryolesion-induced muscle damage.  An 
increased number of proliferating cells (i.e., MyoD+ satellite cells relative to the total number of 
Pax7+ satellite cells) were found 3 days post-injury in both young and old rats receiving the 
leucine supplement compared to the controls (56).  Type II fiber satellite cell proliferation was 
similarly increased in rats provided with the leucine metabolite β-Hydroxy-β-methylbutyrate 
(HMB) during 14 days of reloading after a period of disuse (57).        
Current literature translating these findings to humans is limited, and is mainly focused 
on the relationship between protein or free amino acid supplementation and the exercise-induced 
satellite cell response in older adults.  Farup et al. (58) found that consuming 28 g of whey 
protein after a bout of eccentric exercise increased satellite cell content in the vastus lateralis at 
48 hours compared to the placebo group.  The number of proliferating satellite cells 24 hours 
after a single bout of resistance exercise was also greater in elderly men who consumed 10 g of 
EAAs post-exercise versus those who did not (59).  There may be a limited time course to the 
effect of protein supplementation on satellite cell activity.  The acute satellite cell response to a 
single resistance exercise bout was not different in those consuming a multi-ingredient protein-
based supplement (30 g whey protein, 2.5 g creatine, 400 mg Ca, 500 IU vitamin D, 1 g 
carbohydrate, and 0.75 g n-3 fatty acids) versus those consuming a carbohydrate-based placebo 
for 7 weeks prior to and 48 hours after the exercise bout (60).  It’s possible that exercise-induced 




habituation to the supplement resulted in a similar satellite cell response to exercise between the 
groups at 7 weeks.   
A protein-based intervention also appears to influence satellite cell dynamics when 
implemented before and after total knee arthroplasty (TKA).  Patients that consumed 20 g of 
essential amino acids (EAAs) twice-daily beginning 7 days before their TKA procedure had 
increased satellite cell numbers at the time of surgery (61).  This effect was short-lived even with 
continued supplementation, however, as the number of satellite cells in the EAA group declined 
and were similar to the placebo group at 7 and 14 days post-surgery (61).  Habituation to the 
supplement is one possible explanation for these findings, although it is unclear if the surgery 
itself or the loss of muscle observed in the postoperative period also played a role.  Differences 
in myogenic regulatory factor expression between groups also suggests that EAA 
supplementation after surgery may have altered the activation state of satellite cells without a 
corresponding effect on satellite cell number.  Myogenin expression, for example, was increased 
at weeks 1 and 2 post-surgery in the EAA group and only at week 2 in the placebo group (61).  
Expression of this regulatory factor generally occurs in later phases of the myogenic response 
(62).  This suggests a larger portion of the muscle precursor pool was in a later stage of 
myogenesis in the EAA versus the placebo group at week 1, possibly indicating an accelerated 
myogenic response (61).  These findings are supported by MyoD mRNA expression which was 
only upregulated in the placebo group at 1 and 2 weeks postoperatively (61).  MyoD is expressed 
before myogenin in activated and proliferating satellite cells (62), suggesting a larger portion of 
the muscle precursor pool in the placebo group may have been in earlier stages of myogenesis. 
 




Immune cells localized to a site of skeletal muscle inflammation can generate reactive 
oxidative species (ROS) and cause oxidative stress (63).  Excessive ROS production exacerbates 
skeletal muscle inflammation by activating redox-sensitive NF-κB signaling and downstream 
pro-inflammatory gene expression (64).  The intracellular antioxidant Glutathione (GSH) 
protects against oxidative stress by reacting directly with ROS and producing oxidized GSH 
(GSSG).  Maintaining adequate levels of GSH through recycling of GSSG and de novo synthesis 
is therefore necessary to protect against an excessive oxidative stress-related inflammatory 
response.  De novo synthesis of GSH demands an adequate supply of glutamate (via glutamine), 
cysteine, and glycine that are linked in a 2-step process through action of glutamate cysteine 
ligase and glutathione synthase (65). The branched chain amino acids (BCAAs) leucine, 
isoleucine and valine are significant sources of nitrogen to glutamate and glutamine production 
via transamination (Fig. 2.4). 
 
Figure 2.4   Protein intake modulates skeletal muscle inflammation 
 
By providing an abundance of dietary BCAAs as well as glutamate, cysteine, and 




as GSH precursors.  Whey protein, high in BCAAs and cysteine, has been shown to modulate 
GSH levels of muscle tissue in vitro.  Treating C2C12 muscle cells with whey protein at various 
concentrations (.78 – 6.24 mg protein/mL) increased GSH levels by 25.7% and 138% at the low 
and high concentrations respectively (66).  The antioxidant potential of whey protein is also 
evident in cystic fibrosis patients whose lung inflammation and associated oxidative stress 
increases the demand for GSH.  Consuming 10 g of whey versus 10 g of casein twice daily for 3 
months increased circulating lymphocyte GSH concentrations by 46.6% (67). 
Increasing the supply of exogenous BCAAs through higher protein intakes may also 
augment glutamine availability and have immunomodulatory effects.  Transamination of BCAAs 
with α-ketoglutarate in skeletal muscle generates glutamate that can be used to produce 
glutamine with the incorporation of a free NH3.  Immune system cells require the amino acid 
glutamine to function optimally.  Glutamine addition to cell culture medium increased 
phagocytic activity and enhanced superoxide production in neutrophils and monocytes isolated 
postoperatively from gastrointestinal surgery patients (68).  Rate of lymphocyte proliferation was 
similarly accelerated in vitro in the presence of increasing extracellular glutamine concentrations 
(69).  An abundance of exogenous BCAAs serving as nitrogen donors for skeletal muscle 
glutamine production has therefore been hypothesized to elicit a more efficient and accelerated 
immune response (70).  In support of this concept, Pereira and colleagues (71) observed an 
attenuated inflammatory response and enhanced muscle recovery after muscle injury in rats 
consuming the BCAA leucine.  Supplemental leucine 3 days before and 10 days after cryolesion-
induced muscle damage in young rats attenuated the number of macrophages and area of 
inflammatory cell infiltration at the site of injury (71).  A similar investigation with older rats 




cell infiltration approximately 44% larger than their younger counterparts 10 days after 
cryolesion-induced muscle damage (56).  Supplemental leucine negated this age-related 
difference in area of inflammation, suggesting leucine supplementation has some capacity to 
attenuate an excessive inflammatory response to muscle injury. 
Current literature translating these findings to humans is limited.  Muyskens and 
colleagues (61) provide some of the only insight through their work involving supplementation 
of TKA patients with either 20 g of EAAs or a placebo twice daily for 7 days before and 6 weeks 
after surgery.  Similar to the findings in rats, EAA supplementation after surgery attenuated M1 
macrophage area in vastus lateralis tissue compared to the placebo group (61).  Inflammatory 
cytokine expression was also different between groups.  TNFα mRNA expression in the EAA 
group was elevated 1 week postoperatively and declined by week 2 (61).  In contrast, TNFα was 
only elevated at week 2 in the placebo group (61).  These findings collectively suggest that the 
immune response differed between groups and appears attenuated or accelerated in the EAA 
group.   
 
f. Disuse atrophy as a consequence of musculoskeletal injury  
Acute or repetitive stressors that overload, overstretch, or deform tissues of the 
musculoskeletal system (i.e. muscle, tendon, bone, ligaments) can result in MSI and a 
corresponding loss of function.  Common injuries include muscle strains or contusions, muscle 
or tendon tears, ligament sprains, joint dislocations, and bone fractures.  Surgical interventions 
required to treat some MSIs can also cause further injury.  Total hip arthroplasty (THA) 
procedures, for example, involve unavoidable trauma to muscle surrounding the hip (1).  
Tourniquet use during surgery also causes muscle damage through the associated ischemia and 




Injury-related trauma disrupts normal function of the involved muscle, connective tissue 
or joint.  Inflammation, pain, and swelling of the affected area causes an immediate decline in 
range of motion, neuromuscular signaling, and strength that can persist well after injury.  Knee 
extensor strength in anterior cruciate ligament (ACL) reconstruction patients, for example, was 
66.9% lower one month postoperatively in the injured versus non-injured limb (72).  These 
changes in strength and functional capacity post-injury can be explained in part by underlying 
deficits in neuromuscular signaling.  Musculoskeletal damage and the associated inflammatory 
response alters sensory stimuli, receptor activity, and signal transduction from the injured area to 
the central nervous system.  This is evident following knee joint damage, as swelling, 
inflammation, joint laxity, and damage to articular sensory receptors alters afferent signaling 
from the joint that limits maximal voluntary contraction of the quadriceps muscle (73).    
The loss of neuromuscular signaling and the resulting decline in function following MSI 
constitutes a natural protective response that limits additional structural damage.  Protective 
measures such as prescribed inactivity, immobilization with a cast or brace, and unloading via 
crutches or bed rest may also be implemented to restrict motion and prevent further injury.  
While the loss of neuromuscular signaling and interventions to limit movement aid the healing 
process after MSI, muscle atrophy and weakness occurs rapidly under these conditions given the 
disuse of muscle.  This is evident in experimental models of disuse that have shown a 3.5 and 
8.4% decline in quadriceps cross-sectional area (CSA) in healthy young individuals after only 
five and 14 days of one-legged knee immobilization, respectively (74).  Single-leg 1- repetition 
maximum (1-RM) strength also declined by 9% after 5 days of immobilization and 22.9% after 




The disproportionately greater loss of strength compared to muscle mass during disuse 
indicates there is also a loss of muscle quality (i.e., muscle strength relative to muscle size).  This 
may be explained in part by disuse-induced decreases in fascicle length and pennation angle that 
limit the capacity of muscle fibers to generate force (75).  Diminished muscle quality may also 
result from changes at the single fiber level.  A decrease in single fiber specific force (i.e., 
maximal Ca2+-activated force relative to CSA) of isolated vastus lateralis fibers was observed 
following four (76) and 14 (77) days of unilateral leg immobilization.  A loss of actin or myosin 
protein content (78, 79), changes in Ca2+ sensitivity (76), or other modifications of the contractile 
apparatus that alter active cross-bridge formation may explain the loss of single fiber and whole 
muscle quality with disuse.   
 
g. Mechanisms of muscle disuse atrophy 
Skeletal muscle mass is regulated by rates of MPS and MPB that fluctuate throughout the 
day in response to feeding and fasting.  Hyperaminoacidemia in the postprandial period 
following protein ingestion transiently stimulates MPS (80), while a simultaneous 
hyperinsulinema inhibits MPB (81, 82).  This effect is short-lived, however, as breakdown 
predominates in the postabsorptive period between meals.  Collective rates of synthesis and 
breakdown and the resulting net balance (MPS minus MPB) control changes in muscle mass.  A 
negative net balance (MPS < MPB) maintained over time and resulting from diminished rates of 
MPS, increased MPB, or both, would account for the muscle atrophy observed with disuse.   
i. Muscle protein synthesis and anabolic signaling in disuse atrophy 
Altered rates of MPS have consistently been observed during periods of disuse in young 
populations.  Gibson and colleagues (83) were the first to demonstrate a 25% reduction in fasted 




decline in postabsorptive MPS occurs rapidly and persists with disuse of longer duration.  
Postabsorptive rates of MPS were 40% lower in immobilized versus control limbs after only 5 
days of a full leg cast (84), and were similarly cut in half following 14 days of bed rest (85).  The 
muscle protein synthetic response to protein intake is also blunted with periods of disuse.  This 
“anabolic resistance” to protein ingestion occurs early, as rates of MPS following ingestion of 25 
grams of whey protein were ~53% lower in immobilized versus control limbs after only 5 days 
of a full leg cast (84).  Fourteen days of immobilization similarly blunted rates of MPS with both 
low and high dose amino acid infusions (86).   
The time course and magnitude of disuse-related impairments in postprandial MPS are 
different between young and old populations.  While the synthetic response to feeding was 
maintained after 5 days of bed rest in young individuals (22 ± 1 yr), rates of MPS were 
unresponsive to essential amino acid (EAA) ingestion in older adults (66 ± 1 yr) under the same 
conditions (87).  Quantifying anabolic resistance by evaluating the fate of dietary-derived protein 
(i.e., incorporation into body proteins or irreversible hydroxylation) also revealed greater 
anabolic resistance in old versus young individuals with two weeks of bed rest (88).  Age-related 
differences in postprandial synthetic responses have also been observed under normal conditions.  
Older adults displayed diminished responsiveness of MPS to graded intakes of EAAs (89) and 
required greater amounts of protein to maximally stimulate MPS after resistance exercise versus 
their younger counterparts (90).  Inherent differences in the synthetic response to protein intake 
between old and young individuals (i.e., anabolic resistance with aging) may therefore explain 
the greater anabolic resistance with disuse in older adults, and suggests an age-related 




Cellular mechanisms underlying these changes in MPS with disuse are not fully 
understood.  Protein synthesis is primarily regulated by activation of the mammalian target of 
rapamycin (mTOR) and phosphorylation of several downstream substrates (i.e., 4E-BP1, 
p70S6K, rpS6) that promote mRNA translation initiation. However, activation of this pathway in 
the postabsorptive state remains unchanged with disuse of short (84) and longer duration (86, 
91), indicating the disuse-induced attenuation of postabsorptive MPS occurs independent of 
changes in mTOR-stimulated translation initiation.  Whether disuse alters the regulation of 
elongation (i.e., translation efficiency) or ribosomal biogenesis (i.e., translation capacity) 
downstream of mTOR has not been well characterized in humans and should be a focus of future 
work.  Regulation of protein synthesis can also occur independent of the mTOR pathway through 
phosphorylation of glycogen synthase kinase (GSK)-3β and downstream activation of the 
translation initiation factor eukaryotic initiation factor 2B (eIF2B).  Immobilization for 48 hours 
decreased GSK-3β phosphorylation by 21% (92), suggesting alterations in GSK-3β signaling 
may be linked to the attenuation of postabsorptive MPS with disuse.  It is unclear, however, if 
GSK-3β phosphorylation is decreased with disuse of longer duration or if downstream eIF2B 
phosphorylation is similarly altered. 
Although mTOR signaling appears unrelated to the attenuation of postabsorptive MPS, 
blunted activation of this pathway may explain disuse-related impairments in postprandial MPS.  
Bed rest of five (87) or seven (93) days in older adults blunted the phosphorylation of p70 
ribosomal protein S6 kinase (p70S6K) and ribosomal protein S6 (rpS6) with EAA ingestion.  
EAA-stimulated mTOR signaling was similarly attenuated after 5 days of bed rest in a young 
population, however, this occurred without changes in MPS or lean mass (87).  It was speculated 




synthesis and lean mass that would have been observed in bed rest of longer duration (87).  A 
change in postprandial mTOR signaling was also observed in young individuals after 5 days of 
unilateral leg immobilization.  Phosphorylation of mTOR and 4E binding protein 1 (4E-BP1) 
was decreased relative to fasted values 4 hours post-protein ingestion in immobilized versus 
control limbs (84).  Given that peak stimulation of mTOR signaling is generally observed 1-2 
hours after feeding, the authors concluded the depressed levels of phosphorylated mTOR and 4E-
BP1 at 4 hours indicated reduced transduction of the anabolic signal through this pathway (84). 
While upstream regulators of disuse-induced anabolic resistance are poorly defined, focal 
adhesion kinase (FAK) is a mechanosensitive protein that may connect the loss of muscle 
contraction during disuse with impairments in postprandial mTOR signaling.  Mechanical stimuli 
are sensed by membrane-associated integrin receptors and transmitted via phosphorylation of 
FAK and other downstream kinases (94).  Basal levels of FAK phosphorylation appear sensitive 
to loading as FAK phosphorylation was increased with chronic resistance exercise (95) and 
decreased with disuse of short (96) and longer duration (86, 91).  This load-dependent activation 
of FAK may affect mTOR signaling.  Phosphorylated FAK promotes mTOR activity in vitro by 
phosphorylating and inhibiting tuberous sclerosis complex 2 (TSC2), a negative regulator of 
mTOR (97, 98). A decline in FAK phosphorylation and possible increase in active TSC2 with 
disuse may therefore explain the disuse-induced attenuation of postprandial mTOR activity and 
rates of MPS.  Further in vitro and in vivo investigations are needed, however, to firmly establish 
this relationship.   
The attenuation of mTOR pathway activity underlying anabolic resistance with disuse 
may also result from cellular stress.  The protein regulated in development and DNA Damage 




immobilization) and acts to repress mTOR signaling (99).  An upregulation of REDD2 mRNA 
expression with disuse was first observed following immobilization in rodents (100), and also 
occurred with 5 days of bed rest in young and old individuals (87).  These findings suggest that 
increased expression of REDD2 may be involved in the attenuation of postprandial mTOR 
signaling.  REDD1 mRNA expression was also upregulated with bed rest (87).  This only 
occurred in young individuals, however, indicating the effect of REDD1 on mTOR signaling 
during disuse may be age-dependent.   
ii. Muscle protein breakdown and catabolic signaling in disuse atrophy 
While deficits in MPS are a well-recognized consequence of disuse, less is known about 
the role of protein breakdown in disuse-induced muscle atrophy.  Rates of MPB are seldom 
reported given the technical challenges associated with directly measuring protein degradation in 
vivo in humans.  To our knowledge only two studies have measured rates of MPB during disuse 
conditions and reported no changes with 14 (85) and 21 (101) days of bed rest in young 
individuals.  These findings complement calculations suggesting alterations in MPS alone 
sufficiently account for the loss of muscle mass during disuse and have led to the hypothesis that 
disuse atrophy occurs without appreciable changes in MPB (85, 102).  This contrasts indirect 
measures of MPB (i.e., mRNA expression of proteolytic proteins) that appear to change with 
short-term unloading and may indicate some role of MPB during disuse.       
Breakdown of muscle protein is regulated by the autophagy-lysosomal system, calcium-
dependent calpains, caspase enzymes, and the ubiquitin proteasome system (UPS).  The UPS, in 
particular, is largely responsible for the degradation of myofibrillar proteins through enzymatic 
activity of the muscle-specific ubiquitin ligases muscle ring fiber 1 (MuRF1) and muscle atrophy 




several conditions of muscle atrophy (104).  Immobilization of 2-14 days, for example, elevated 
mRNA expression of MAFbx and/or MuRF1 in young individuals (84, 91, 105-107).  In 
contrast, transcript levels of these proteins remained unchanged or decreased compared to 
baseline in other studies of disuse lasting 14 - 24 days (78, 91, 107).  The time-dependent 
expression of these static markers of proteolysis suggest MPB increases early with the onset of 
disuse and returns to baseline with inactivity of longer duration as hypothesized by Wall and 
colleagues (108).  Changes in proteolytic gene expression do not always translate to changes in 
protein content (109) or measured rates of MPB (82), however, indicating future work must use 
dynamic measures of proteolysis (i.e., stable isotope methodology) to confirm the proposed early 
increase of MPB rates with disuse.   
Disuse may also alter postprandial rates of MPB.  Insulin released with protein feeding 
modulates glucose metabolism and suppresses MPB (81, 82).  Sensitivity to this insulin stimulus 
appears to decline with disuse, however, as impairments in whole-body and muscle glucose 
uptake in response to insulin were observed with bed rest (110) and immobilization (111), 
respectively. Whether disuse leads to insulin resistance of protein metabolism is less clear.  Work 
by Richter et al. (111) using a two-step euglycemic hyperinsulinemic clamp procedure showed 
that the normal hyperinsulinemia-induced attenuation of MPB may be impaired with 7 days of 
immobilization.  Arterial tyrosine concentrations were measured to assess net protein breakdown 
as tyrosine is not synthesized or catabolized in muscle.  The greater tyrosine release with insulin 
infusion in immobilized versus control limbs suggests MPB was less sensitive to inhibition by 
insulin under disuse conditions (111).  Whether these findings extend to protein feeding during 
disuse is unknown, however, given current methodical limitations associated with directly 





h. Protein as a countermeasure to muscle disuse atrophy 
Attenuating muscle losses and preserving muscle function with disuse may require 
interventions to overcome the observed decline in MPS (postabsorptive and postprandial) and 
possible early increase in MPB.  Muscle protein turnover is modulated primarily by dietary 
protein in the absence of muscle contraction.  Optimizing the anabolic response to protein intake 
may therefore be one way to increase MPS and overcome anabolic resistance to preserve muscle 
mass with disuse.  Twenty grams of high-quality protein have been shown to maximally 
stimulate MPS under normal physiological conditions in young individuals (112), while greater 
amounts (~35 g) were needed to overcome the anabolic resistance observed with aging and 
achieve maximal rates of MPS in an elderly population (113).  Larger quantities of protein may 
similarly be necessary to overcome disuse-induced anabolic resistance.  Other strategies to 
overcome anabolic resistance include manipulating the EAA and/or leucine content of the diet.  
Considerable work has shown that the EAA component of protein is responsible for stimulating 
MPS (114, 115), while leucine in particular has been identified as a ‘trigger’ for the synthetic 
response (116).  Several studies have therefore manipulated the protein, EAA, or leucine content 
of the diet in an effort to attenuate muscle atrophy during a period of experimental disuse (i.e., 
bed rest or immobilization in healthy populations) with mixed results. 
Protein or amino acid supplementation has been shown to protect lean mass in several 
studies of disuse.  Early work by Paddon-Jones et al. (117) found that supplementing a controlled 
diet with 16.5 g of EAAs plus 30 g of sucrose three times a day maintained leg lean mass and 
partially preserved strength in young adults subjected to 28 days of bed rest.  Leucine 
supplementation (4.4 g per meal) similarly attenuated declines in knee extensor peak torque, 




aged adults (118).  Whole-body lean mass was only preserved during the first week, however, 
suggesting a limited time course for the protective effect of leucine supplementation on lean 
mass during disuse (118).  Supplementation with the leucine metabolite β-hydroxyl-β-
methylbutyrate (HMB) during 10 days of bed rest also preserved whole body lean mass (119).  
Protein intake was only at the current recommended dietary allowance (RDA) of 0.8 g/kg/d in 
the control group, however, which may be inadequate in older populations (120).  The benefit of 
the intervention may therefore reflect adequate protein intake rather than a protective effect of 
HMB itself (121). 
Additional literature has reported a muscle-preserving effect of protein-based 
interventions without a corresponding change in muscle function.  Consuming ~66.8 g of a 
proprietary amino acid-containing formulation on top of a diet providing 1.0 g/kg/d, for example, 
attenuated muscle losses with 7 days of immobilization, while declines in knee extensor strength 
remained unaffected by the intervention (122).  A trend for the partial protection of leg lean mass 
(p=0.08) with no change in strength outcomes was also observed when high-quality whey protein 
was incorporated into the diet of healthy older men and women during 7 days of bed rest (123).  
In contrast, EAA supplementation has also been shown to preserve muscle function during 
disuse with no effect on lean mass losses.  Older adults consuming 15 g of EAA three times daily 
during 10 days of bed rest lost similar amounts of total and leg lean mass compared to the control 
group, while muscle function outcomes (e.g., floor transfer time) were only preserved in those 
consuming the EAA supplement (124).    
Although protein or amino acid supplementation appears to have some benefit during 
disuse, it is not always protective under these conditions.  Daily supplementation of 20 g of whey 




atrophy or protect isometric knee extension strength, single leg jump height, or peak power 
production during an incremental cycling test (125).  Dirks et al. (126) similarly observed no 
benefit of twice daily consumption of a leucine-enriched whey protein supplement on protecting 
lean mass or single-leg 1-RM strength during 5 days of a full leg cast in older adults.  Adding 2.5 
g of leucine to every meal during 7 days of immobilization in young adults also had no effect on 
preserving muscle mass or function (127) despite the previously reported benefit during 7 days 
of bed rest (118).  Dividing up and consuming an additional 3.6 g leucine, 1.8 g valine, and 1.8 g 
isoleucine over 3 meals during 60 days of bed rest was also ineffective, and actually lead to a 
greater loss of thigh muscle volume compared to the control group (128).   
The heterogeneity of these studies makes it challenging to precisely understand why 
muscle mass and/or muscle function is protected in some cases but not others.  Differences in 
model and duration of disuse, subject age, and outcomes measured may all contribute to the 
inconsistent findings.  Protein-based interventions during disuse of varying durations (5 – 60 
days) may not be comparable given the proposed difference in mechanisms underlying short- 
versus long-term disuse (108).  Results from different age groups (i.e., young, middle-aged, and 
elderly adults) should also be compared cautiously given the previously discussed susceptibility 
of older adults to anabolic resistance during disuse that may influence the effectiveness of 
particular interventions.  Differences in methods used to measure muscle mass and muscle 
function during disuse may also contribute to variable findings.  Results obtained from isokinetic 
dynamometry and 1-RM testing, for example, were not equivalent in assessing the efficacy of a 
resistance training intervention (129) suggesting studies using these different methods to 




The wide variety of protein and free amino acid supplementation protocols tested during 
disuse may also contribute to inconsistent findings.  There is currently a poor understanding of 
what would constitute an optimal protein-based intervention.  While one objective of these 
countermeasures is to overcome disuse-induced anabolic resistance, no study to date has 
determined if this can be done with greater amounts of protein, EAAs or leucine, or if there is a 
threshold for maximally stimulating postprandial MPS with disuse (130).  Whether the different 
protein or free amino acid interventions tested in current literature had the capacity to overcome 
disuse-induced anabolic resistance is therefore unclear.  Some insight comes from Wall et al. 
(84) who showed that postprandial rates of MPS following ingestion of 25 g of whey protein 
(10.9 g EAA, 2.7 g Leucine) were cut in half with 5 days of a full leg cast.  These findings 
suggest the ~21 g of leucine-enriched whey protein (10.6 g EAA, 2.8 g leucine) consumed 
immediately after breakfast and before sleep during 5 days of immobilization in a separate study 
(126), may not have been sufficient to overcome anabolic resistance in the absence of additional 
protein consumed at these time points.  This may explain the similar loss of quadriceps CSA and 
1-RM strength observed in the protein supplement and control group.   
Further understanding of mechanisms underlying the loss of muscle mass and function 
with disuse may also clarify inconsistent findings and explain why some interventions 
maintained muscle mass and/or function and why others were ineffective.  As discussed 
previously, it is unknown if disuse leads to an early increase in MPB or if postprandial rates of 
MPB are greater with disuse.  Whether an abundance of exogenous amino acids from protein or 
amino acid supplements would spare the breakdown of body proteins in the fed and/or fasted 
state or if interventions should target this is or not is unclear.  Future work should also establish 




corresponding changes in muscle mass.  It is possible that stimulating protein turnover in these 
studies (118, 123) facilitated the removal and replacement of aged or damaged proteins in what 
has been described as ‘nonhypertrophic’ remodeling (131), resulting in better muscle quality and 
improved function of contractile units that would explain the preserved function.  This remains 
to be determined, however.   
 
i. Protein to support rehabilitation following musculoskeletal injury 
While protein-based interventions appear to have some capacity to protect skeletal 
muscle mass and function with disuse, the most effective countermeasure is simply muscle 
contraction in the form of electrical stimulation or resistance exercise.  Muscle contraction is a 
potent stimulus for MPS, even in disused muscle.  Gibson et al. (132) were the first to show that 
daily percutaneous electrical stimulation of quadriceps muscle during 6 weeks of immobilization 
for tibial fracture was sufficient to maintain rates of postabsorptive MPS in the immobilized 
limb.  Exercising knee extensors to volitional muscle failure every other day using a horizontal 
leg-training device similarly attenuated the decline of fasted-state MPS observed with 14 days of 
bed rest (133).  Exercise also sensitizes skeletal muscle to the anabolic effect of protein ingestion 
(134), suggesting disuse-induced anabolic resistance may similarly be attenuated with some form 
of muscle contraction.  The effect of exercise on rates of MPS translates to the preservation of 
muscle mass during disuse.  Neuromuscular electrical stimulation (NMES) for 40 minutes twice 
a day preserved quadriceps CSA during 5 days of one-legged knee immobilization (105).  Thigh 
CSA and isometric knee extensor strength were similarly preserved during 14 days of 
immobilization by low-volume, high-intensity resistance exercise (i.e., 80% 1-RM) (135).        
Protecting muscle during disuse conditions using exercise or electrical stimulation is not 




introduce exercise and activation of muscle as early as possible after MSI.  Given the physical 
constraints associated with injuries themselves, resistance exercise at workloads shown to 
increase MPS (133) or preserve muscle mass and function during disuse (135) are generally not 
possible.  Early rehabilitation instead focuses on mobilization and activation of muscle through 
body weight or light-load resistance exercise often performed to fatigue.  Surrogates for muscle 
contraction (i.e., NMES) are also generally incorporated into standard rehabilitation.  Unloading 
and disuse of muscle following MSI is therefore accompanied by periodic muscle activation 
during rehabilitation.  This must considered when translating and implementing findings from 
protein-based interventions in experimental disuse conditions to disuse following MSI.   
Whether light-load resistance exercise or electrical stimulation of muscle during 
rehabilitation has a stimulatory effect on rates of MPS or improves sensitivity of muscle to 
protein ingestion is not completely understood.  Some insight comes from Wall and colleagues 
(136) who showed that one hour of high-frequency, high-intensity NMES in elderly men 
increased postabsorptive MPS by ~27% compared to the non-stimulated leg.  The pre-sleep 
application of NMES plus ingestion of 40 g of protein after 1 day of bed rest also increased 
overnight MPS, suggesting NMES can potentiate the anabolic response to protein intake in 
disuse conditions (137).  The anabolic potential of light load resistance exercise normally and 
with disuse is less clear.  A single bout of low intensity resistance exercise (i.e., 16% 1-RM) 
comparable to what would be performed during rehabilitation was unable to increase rates of 
myofibrillar protein synthesis in the fed state or potentiate the synthetic response to feeding 
(138).  Twelve weeks of resistance training at this same intensity led to a small (~3%) but 
significant hypertrophy of muscle, however, indicating an anabolic potential for this type of 




the elevation of myofibrillar protein synthesis during 10 hours of hyperaminoacidemia, 
suggesting there was an increased sensitivity of muscle to protein feeding that allowed more 
amino acids to be stored as contractile proteins (140).  These findings indicate that electrical 
stimulation of muscle and light-load resistance exercise in early rehabilitation combined with 
protein-centered diet interventions would have a synergistic effect at increasing rates of MPS, 
overcoming anabolic resistance, and protecting muscle mass and function from disuse after 
injury. 
While research translating this concept to practice by implementing protein-based diet 
interventions during early rehabilitation from MSI remains limited, available literature suggests 
some benefit to free amino acid supplementation in the pre- and post-operative period following 
orthopedic surgery.  Consuming 20 g of EAAs twice a day for 7 days before and 6 weeks after 
total knee arthroplasty (TKA), for example, attenuated the loss of quadriceps muscle volume 
when compared to the placebo group at 2 weeks (-3.4 ± 3.1 % vs. -14.3 ± 3.6 %) and 6 weeks (-
6.2 ± 2.2 % vs. -18.4 ± 2.3%) postoperatively (141).  EAA supplementation also accelerated the 
return of functional mobility (i.e., timed up-and-go, stair-climb up, and stair-climb down tests) at 
6 weeks compared to the placebo group (141).  These findings must be interpreted with caution, 
however, given the decrease in total amount of dietary protein consumed in the placebo group 
during the intervention.  While protein intake was close to the current RDA of 0.8 g/kg/d at 
baseline and 6 weeks, it fell to 0.63 ± 0.09 g/kg/d in the placebo group at 2 weeks post-surgery 
(141).  This may have exacerbated the loss of muscle volume and function observed in these 
individuals.  A follow-up study of the same intervention also observed a decrease in protein 
intake from baseline to week 2, however the reduction was similar in both group (142).  




placebo group (-8.5±2.5% vs. -13.4±1.9%), while differences between groups in functional 
measures or strength were no longer observed (142).  Ferrando et al. (143) also evaluated the 
utility of EAA supplementation after orthopedic surgery by randomizing total hip arthroplasty 
(THA) patients to receive usual care (UC) or to consume 15 g of EAAs three times a day for 8 
weeks after surgery.  Quadriceps maximal voluntary contraction was 35% greater than 
preoperative values at 8 weeks post-surgery in the EAA group, while strength did not improve in 
those receiving UC (143).  Supplementation with 2.4 g of HMB, 14 g of L-arginine, and 14 g of 
L-glutamine (HMB/Arg/Gln) twice daily for 5 days before and 28 days after TKA also has been 
shown to benefit strength outcomes.  Maximal quadriceps strength declined from baseline at 2 
weeks post-surgery in the control group, while the HMB/Arg/Gln intervention preserved strength 
at this time point (144).      
 
j. Testosterone-mediated regulation of muscle mass 
Exogenous testosterone administration has consistently been shown to induce skeletal 
muscle hypertrophy.  Replacement doses of testosterone enanthate (100 mg/wk) led to greater 
arm and leg muscle cross-sectional area (CSA) in healthy, hypogonadal men (145), and 
increased muscle volume in HIV-infected men with weight loss and low testosterone levels 
(146).  Muscle hypertrophy has also been observed in eugonadal men receiving 
supraphysiological doses of testosterone.  Weekly administration of 125, 300 or 600 mg of 
testosterone enanthate along with monthly injections of a long-acting gonadotropin-releasing 
hormone (GnRH) agonist to suppress endogenous testosterone secretion, dose-dependently 
increased fat-free mass in healthy young men after 20 weeks by 3.4, 5.2, and 7.9 kg, respectively 
(147).  Although the hypertrophic effect of exogenous testosterone administration is well-




Muscle mass is regulated by rates of muscle protein synthesis (MPS) and muscle protein 
breakdown (MPB) that fluctuate throughout the day in response to anabolic (i.e., feeding) and 
catabolic (i.e., fasting) stimuli.  A persistent positive net balance (MPS > MPB) resulting from an 
increase in MPS, decrease in MPB, or both, would lead to lean mass accretion over time.  
Muscle mass is also regulated through activity of normally quiescent adult muscle stem cells 
(i.e., satellite cells) that repair or remodel muscle tissue when activated by forming new 
multinucleated myotubes that fuse with existing fibers (4, 131).  Current literature suggests 
testosterone exerts its hypertrophic effect by acting on MPS, MPB, or satellite cell activity.    
i. Testosterone and myogenesis  
Exogenous testosterone administration has been shown to modulate satellite cell 
dynamics in animal models and in humans.  Testosterone treatment before the onset of puberty in 
male and female rats, for example, transiently increased satellite cell content of androgen-
responsive muscle groups and increased the number of myonuclei (148).  Sinha-Hikim et al. 
(149) similarly observed a dose-dependent increase in satellite cell number following weekly 
administration of 300 or 600 mg of testosterone enanthate in men given a GnRH agonist, along 
with greater muscle CSA and myonuclear number.  The increased number of satellite cells and 
their subsequent fusion with muscle fibers likely gave rise to the greater myonuclear content 
observed in both studies given that muscle fiber nuclei are postmitotic.  These findings 
collectively indicate a direct regulation of satellite cells by testosterone that may underlie its 
hypertrophic effect in muscle. 
While it appears testosterone increases the number of satellite cells and their fusion with 
existing fibers, the mechanisms underlying this effect are not fully understood.  Activated 




rapidly in response to the sequential expression of specific transcription factors (i.e., Pax7, Myf5, 
MyoD, myogenin, and MRF4).  A portion of the activated satellite cells also return back to 
quiescence to replenish the stem cell pool.  Testosterone administration in humans has been 
shown to increase the number of proliferating cell nuclear antigen positive (PCNA +) satellite 
cells and the expression of myogenin in muscle, indicating testosterone promotes cell cycle entry 
and later stages of myogenesis (150).  These findings are supported by in vitro models showing 
testosterone enhanced proliferation (151, 152) and differentiation (151, 153) of cultured 
myoblasts.  Additional in vitro studies have reported no change in proliferation (153, 154) or 
reduced differentiation (154) with testosterone administration, indicating future work is needed 
to define a clear mechanism of action.  Testosterone may also contribute to the formation of new 
myotubes via action on uncommitted, pluripotent mesenchymal stem cells that are capable of 
differentiating into muscle, fat cartilage, and bone cells.  Incubating mouse mesenchymal C3H 
10T1/2 cells with testosterone or dihydrotestosterone (DHT) dose-dependently increased the 
mRNA and protein levels of MyoD and myosin heavy chain II (MHC), indicating testosterone 
can recruit mesenchymal pluripotent cells into the myogenic lineage (155).    
The androgen receptor (AR) appears to mediate some of the effects of exogenous 
testosterone administration on satellite cells activity and the myogenic response.  Expression of 
AR has been shown to increase in muscle following androgen treatment in rats (156) and humans 
(157).  While AR is found in several cell types, satellite cells are the predominant site of AR 
expression in human skeletal muscle (158), suggesting the increase in AR following testosterone 
treatment may be linked to changes in satellite cell activity.  AR exerts an effect by binding 
androgens that cross the cell membrane.  The resulting complex translocates to the nucleus and 




genes.  Lee et al. (153) have reported a relationship between androgen-AR signaling and the 
upregulation of myogenin expression in C2C12 myoblasts.  Androgens also appear to regulate 
myogenic differentiation of mesenchymal multipotent cells by inducing an interaction between 
AR and β-catenin to activate T-cell factor-4 (TCF-4) target genes (159). 
Testosterone may also promote satellite cell proliferation and differentiation through AR-
independent mechanisms.  Proliferation and differentiation were enhanced in skeletal muscle 
myoblast L6 cell lines (L6 cells) lacking the classical AR following the addition of exogenous 
testosterone or a form of testosterone that wouldn’t cross the cell membrane (151).  This effect 
was determined to be dependent on G-protein coupled receptors at the plasma membrane (151).  
This is in line with work from Estrada et al (160) showing testosterone induced a rapid change in 
intracellular Ca2+ levels through G-protein coupled receptor activity in rat myotubes, and 
suggests testosterone may promote satellite cell proliferation and differentiation through AR-
independent signaling pathways.   
Androgen action on satellite cell dynamics may also occur though the modulation of 
upstream inflammatory signaling.  While a transient increase in local pro-inflammatory cytokine 
expression mediates the repair and regeneration of damaged myofibers through myogenesis, 
exceedingly high or chronic inflammation can inhibit the myogenic response and induce muscle 
atrophy.  In vitro studies have shown that the production of the inflammatory cytokines TNFα, 
IL-1β, and IL-6 in human macrophages (161) and monocytes (162) is attenuated with the 
addition of testosterone to culture media.  Androgen treatment in prostate cancer cells has also 
been shown to suppress activity of NFκB (163), a regulator of pro-inflammatory cytokine 
expression.  This anti-inflammatory effect of testosterone has also been observed in human 




decreased in skeletal muscle of elderly men following 7 days of testosterone treatment (164).  
Whether the modulation of inflammation by testosterone influences satellite cell activity is 
unclear.   
ii. Testosterone and muscle protein synthesis  
Exogenous testosterone administration has been shown to alter dynamic rates of protein 
synthesis under fasted, but not fed, conditions.  Protein synthesis was increased and breakdown 
was unchanged, for example, five days after intramuscular injection of 200 mg of testosterone 
enanthate in healthy, young men (165).  Increased rates of protein synthesis following an 
overnight fast were also observed in older men (~ 67 y) given testosterone injections for four 
weeks (166).  It appears that exogenous testosterone administration does not change synthetic 
rates following amino acid feeding (167, 168).  Protein synthesis was also unchanged when the 
supplementation protocol raised levels of androgens from a lower physiological/hypogonadal 
range to the normal physiological range (157, 167).  These findings suggest that the effects of 
exogenous testosterone on rates of protein synthesis are related to testosterone concentration 
prior to measurement (i.e., hypogonadal versus supraphysiological) and metabolic state of an 
individual (i.e., fed versus fasted) (169).   
Molecular mechanisms underlying the effect of androgens on protein synthesis are not 
fully understood.  An increase in protein synthesis following an anabolic stimulus involves 
signaling through mTOR and the phosphorylation of several downstream targets (i.e., 4E-BP1, 
p70S6K, rpS6) that promote mRNA translation initiation.  Increased signaling through this 
pathway and modulation of upstream effectors such as insulin-like growth factor-1 (IGF-
1)/phosphatidylinositol 3-Kinase (PI3K)/Akt and extracellular signal-related kinase 1/2 




myotube hypertrophy in primary rat myoblasts was accompanied by activation of ERK1/2 and 
Akt, as well as downstream S6K1 phosphorylation (170).  Inhibiting PI3K/Akt or mTOR 
negated the increase in CSA observed at 12 hours (170).  Inhibiting AR also attenuated myotube 
CSA, suggesting AR as well as Akt/mTOR signaling are essential in coordinating the 
hypertrophic response to supplemental testosterone (170).  In line with these findings, Wu et al. 
(171) reported that testosterone-induced increases in protein synthesis were blocked by the 
mTOR inhibitor rapamycin.  Androgen withdrawal in rats through castration or nandrolone 
decanoate (ND) treatment also decreased myofibrillar protein synthesis through Akt/mTOR 
signaling (172). 
It is unclear if the relationship between testosterone and mTOR signaling observed in vitro 
translates to humans.  Although cell and animal studies have identified a link between 
testosterone and mTOR pathway signaling, this work may not accurately reflect the fasted 
conditions under which testosterone-induced increases in protein synthesis have been observed 
in humans (169).  Rossetti et al. (169) have suggested that mechanistic studies must employ 
periods of fasting in animal models and serum or nutrient deprivation prior to harvesting cultured 
cells to more accurately understand molecular signaling underlying the androgen-mediated 
increase in protein synthesis observed under fasted metabolic conditions.  Whether mTOR 
signaling regulates rates of synthesis during basal, non-stimulated conditions is not fully 
understood.  Work from Dickenson et al. has shown that treating humans with the mTOR 
inhibitor rapamycin only altered rates of muscle protein synthesis in the fed (173) but not the 
fasted state (174).  This suggests other signaling pathways may be involved in regulating rates of 
protein synthesis under fasted conditions.        




Androgen-mediated changes in MPB have been observed in some, but not all, studies of 
exogenous testosterone administration in humans.  Testosterone enanthate injection in older men 
(~67 y) whose pretreatment testosterone levels were in the lower physiological/hypogonadal 
range, for example, decreased rates of MPB (157, 167).  In contrast, MPB was unchanged five 
days after a single testosterone or oxandrolone injection in young males (165, 168).  Differences 
in age as well as pretreatment and posttreatment androgen levels (i.e., hypogonadal to 
physiological vs. physiological to supraphysiological) may explain these contrasting outcomes 
(169).  Whether testosterone influences MPB after feeding is unknown given current methodical 
limitations associated with directly measuring MPB following protein ingestion. 
The ubiquitin proteasome system (UPS) is largely responsible for the degradation of 
myofibrillar proteins through enzymatic activity of the muscle-specific ubiquitin ligases MAFbx 
and MuRF1.  These markers of MPB are altered in some, but not all, studies of exogenous 
testosterone supplementation.  Transcript levels of MAFbx and MuRF1 were not altered with 
administration of supraphysiological concentrations of testosterone (100 nM) in primary rat 
myotubes (170) or in soleus muscle of androgen-treated mice (175).  In contrast, MAFbx and 
MuRF1 expression increased in androgen-sensitive rat skeletal muscle with castration, and was 
fully repressed with acute testosterone administration (176).  Work by Zhao et al. (177) has also 
shown that testosterone represses MAFbx expression through AR-dependent signaling in C2C12 
cells.  Discrepancies between studies may be related to choice of model or the metabolic state of 
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Perioperative markers of intramuscular inflammation and myogenesis are associated with 
muscle recovery outcomes following Anterior Cruciate Ligament reconstruction: potential 




Quadriceps muscle atrophy and weakness are well-recognized clinical outcomes of 
anterior cruciate ligament (ACL) reconstruction that can persist after surgery despite aggressive 
physical rehabilitation efforts (1, 2).  Failing to reverse these deficits in muscle mass and strength 
can negatively impact activities of daily living, physical performance, and quality of life.  The 
etiology of postoperative muscle atrophy and weakness is complex.  Deficits in neuromuscular 
signaling as well as protective measures implemented to avoid further injury (i.e., 
immobilization, inactivity) induce a rapid loss of muscle mass and function due to the unloading 
and reduced neural activation of muscle (3, 4).  The involvement of intramuscular inflammatory 
signaling and satellite cell content (i.e., regenerative potential) in the muscle atrophy and loss of 
function observed in the postoperative period is less clear.   
Repair or replacement of damaged muscle fibers via myogenesis contributes to the 
maintenance of muscle mass and function (5-7).  This nonhypertrophic remodeling involves 
activation of muscle resident stem cells (i.e., satellite cells) and the coordinated expression of 
several regulatory factors (i.e., Pax7, Myf5, MyoD, myogenin, and MRF4) that initiate their 
subsequent proliferation and differentiation.  Exceedingly high or chronic inflammation can 
inhibit this myogenic response and induce muscle atrophy.  High concentrations of tumor 
necrosis factor-α (TNFα) and TNF-like weak inducer of apoptosis (TWEAK) in cultured 




11) and led to a loss of total protein content (12, 13).  Infusion of soluble interleukin 6 (IL-6) into 
rat hindlimb muscle similarly decreased myofibrillar protein content compared to untreated 
contralateral muscle (14).  Bamman and colleagues (15) hypothesized that increased muscle 
inflammation, altered satellite cell dynamics, or both, would exacerbate the disuse-induced loss 
of muscle mass and function and limit muscle regenerative capacity during postoperative 
recovery. 
Intramuscular inflammatory signaling and the abundance or activity of satellite cells may 
be influenced by dietary protein intake.  The number of proliferating satellite cells 24 hours after 
a single bout of resistance exercise was greater in individuals who consumed 10 g of essential 
amino acids (EAAs) post-exercise versus those who did not (16).  Twice daily EAA 
supplementation for 1 week prior to total knee arthroplasty (TKA) also increased satellite cell 
content of vastus lateralis muscle on the day of surgery versus a placebo (17).  Findings from cell 
and animal models suggest that an abundance of branched chain amino acids (BCAAs) in dietary 
protein may improve redox protection and attenuate oxidative stress-related inflammatory 
signaling given the role of these amino acids as precursors for the intracellular antioxidant 
Glutathione (GSH) (18-20).  While research translating these effects to humans is limited, the 
possibility that manipulating protein intake preoperatively would promote satellite cell activity 
and attenuate intramuscular inflammation to optimize postoperative muscle recovery potential 
exists.  
The primary objective of this study was to determine whether a high quality protein-
based diet intervention providing ~2.0 g protein·kg-1·d-1 for two weeks prior to ACL 
reconstruction would modulate skeletal muscle inflammation and increase myogenic regulatory 




secondary analysis of a subset of subjects was also performed to assess the relationship between 
inflammatory and myogenic signaling on the day of surgery and postoperative recovery 
outcomes (i.e., quadriceps strength and thigh circumference).  We hypothesized that: 1) higher 
protein intakes before surgery would improve recovery potential by attenuating inflammation 
and promoting satellite cell activation and 2) that exceedingly high intramuscular inflammation 
and lower myogenic regulatory factor expression at the time of surgery would be associated with 




This study was approved by the Institutional Review Boards at Hartford Hospital 
(Hartford, CT) and the University of Connecticut (Storrs, CT).  All subjects were informed of the 
purpose of the study, the experimental protocol, and all potential risks before giving written 
informed consent to participate.  Five men aged 19 - 39 who were scheduled to undergo their 
first ACL reconstruction were recruited to participate.  Subjects were identified by two 
participating surgeons and subsequently screened by study personnel for all eligibility 
requirements.  Exclusion criteria included body mass indexes (BMIs) greater than 30, metabolic 
or cardiovascular abnormalities, food allergies, and gastrointestinal disorders (i.e., lactose 
intolerance).  Individuals reporting use of nutritional/herbal supplements, anabolic steroids, and 






Figure 3.1.  Experimental Design  
 
This study was a two-arm, parallel trial design with subjects randomly assigned (1:1 
randomization) to an adequate protein (AP) or optimal protein (OP) group providing 1.0 or 2.0 g 
protein·kg-1·d-1, respectively (Fig. 3.1).  The diet intervention began 2 weeks prior to surgery and 
continued for 16 weeks postoperatively during which subjects participated in twice-weekly 
physical therapy.  It should be noted that only data through the first 8 weeks of rehabilitation are 
presented for the purpose of this study to highlight the effects of protein and inflammation on 
early recovery outcomes.  Thigh circumference was measured at baseline before surgery and 
again at 2, 4 and 8 weeks postoperatively.  Maximal quadriceps isometric strength (i.e., peak 
force) was measured at baseline before surgery and again at 8 weeks.  All recovery outcomes 
were measured by the same physical therapist assistant who was well-trained in all study 
procedures.  A muscle biopsy of the vastus lateralis was collected at the time of surgery for 
skeletal muscle protein and gene expression analyses.   
Diet interventions 
Subjects followed a eucaloric (weight maintenance) diet providing 1.0 versus 2.0 g 
protein·kg-1·d-1 (AP vs. OP), 30% of energy intake from fat, and remaining calories from 
carbohydrates starting 2 weeks before surgery and continuing for 16 weeks postoperatively.  One 




Individual energy requirements were established relative to estimated resting energy expenditure 
(Harris-Benedict equation), level of physical activity, and estimated energy intake reported at 
baseline.  Subjects were given 1-week cycle menus individualized based on energy requirements 
and information obtained about their routine food consumption.  Five servings (3 oz) of beef per 
week were provided as a high-quality protein to individuals in the OP group.  Post-rehabilitation 
supplements were integrated into the overall diet design with one serving of IsoPrime BeefTM or 
an isocaloric serving of Powerade® provided to the OP and AP groups, respectively, for 
consumption after physical therapy sessions.  Analyses determining the amino acid and 
macronutrient composition of the beef-based supplement were performed by Covance 
Laboratories Inc. (Madison, WI) and summarized in Table 3.1.  Subjects consumed 4 servings of 
their designated supplement at home during the 2-week diet intervention before surgery to 
maintain consistency with the twice weekly supplement post-rehabilitation in the postoperative 
period.  A 7-day food record beginning 1 week prior to surgery was collected to evaluate dietary 
intake during the pre-surgery diet intervention.  Food records were analyzed using Nutritionist 
ProTM software (Axxya Systems, Woodinville, WA) to estimate total energy and protein intake, 
as well as branched chain amino acid content of the diet.   
    
Table 3.1.  Isoprime BeefTM supplement composition 
Calories (kcal) 100      Amino Acids (mg) 
Total Fat (g) 0         Aspartic Acid 1490        Leucine 957 
Total Carbohydrate (g) 1         Threonine 525        Tyrosine 271 
Protein (g) 25         Serine 753        Phenylalanine 589 
         Glutamic Acid 2620        Lysine 976 
         Proline 2770        Histidine 259 
         Glycine 4800        Arginine 1810 
         Alanine 1960         Cystine 14 
         Valine 650        Methionine 248 





ACL reconstruction surgery  
Subjects were admitted on the morning of surgery in a fasted state.  They were initially 
anesthetized with intravenous propofol and maintained with inhalation anesthetic (sevoflurate) 
during surgery.  Subjects also received regional anesthesia preoperatively consisting of an 
adductor canal and geniculate nerve block using 0.25% Marcaine with 1:200,000 epinephrine.  A 
pneumatic tourniquet was applied ‘as-high-as-possible’ on the thigh of the injured limb during 
sterile preparation and draping.  The lower extremity was exsanguinated and the tourniquet was 
inflated to a pressure of 250 mm Hg immediately prior to incision.  The tourniquet was deflated 
following the graft harvest and muscle biopsy in three subjects (~16 minutes) and not until the 
end of surgery in two (~70 minutes).  All ACLs were arthroscopically repaired with a bone-
tendon-bone (BTB) autograft.  One subject had a ruptured ACL with a concomitant meniscal 
root tear that also required surgical repair.  While this did not influence the analysis of muscle 
tissue collected on the day of surgery, a meniscal repair necessitates a more prolonged period of 
restricted weight bearing and range of motion to protect the healing tissue.  This individual was 
therefore excluded from analyses involving postoperative thigh circumference and strength given 
the altered rehabilitation and recovery after surgery.  The remaining four subjects were non-
weight bearing until their first postoperative visit with the physician (~ 7 days).  This consisted 
of immobilizing the knee with a leg brace locked between 0° and 10° of flexion and using 
crutches.  Subjects were then cleared to progress with weight bearing as tolerated (WBAT) and 
to begin twice weekly physical therapy.  
Postoperative rehabilitation protocol  
 All rehabilitation was done by the same physical therapy assistant and following the 




I) and phase-specific exercises (Appendix II).  Subjects were considered noncompliant with the 
rehabilitation protocol if they missed more than 4 physical therapy sessions total or two sessions 
in a row during the full 16-week diet intervention.   
Muscle biopsy 
Approximately 100 – 200 mg of vastus lateralis muscle tissue was collected during 
surgery with Rongeur forceps through the incision used for the ACL reconstruction.  This 
occurred within 5 minutes of tourniquet inflation at the beginning of surgery.  Collected muscle 
was carefully dissected to remove all visible fat and connective tissue and placed in a vial that 
was snap frozen in liquid nitrogen.  Samples were stored at -80°C until later analyses.   
mRNA expression 
TRIzol reagent (ThermoFisher, Waltham, MA) was used to isolate total RNA from ~20 
mg of muscle to determine expression of several genes linked to skeletal muscle inflammation 
and myogenesis.  Quantity and quality of isolated RNA was assessed using a NanoDrop ND-
2000 spectrophotometer (NanoDrop, Wilmington, DE).  Equal amounts of total RNA (500 µg) 
were reverse-transcribed into cDNA (High-Capacity cDNA RT Kit, Applied Biosystems, Foster 
City, CA) using a T100TM Thermal Cycler (Bio-Rad, Hercules, CA).  Samples were run in 10 µL 
reactions and in duplicate using TaqMan® fast advanced master mix in a Step One Plus Real-
Time PCR system (Applied Biosystems).  mRNA expression levels of IL6 receptor (IL-6R, 
TNFα receptor (TNFα-R), TWEAK, fibroblast growth factor-inducible 14 (Fn14), paired box 7 
(Pax7), MyoD, Myogenin, myogenic factor 5 (Myf5), and myogenic regulatory factor 4 (MRF4) 
were determined using commercially available TaqMan® probes (Applied Biosystems).  Data 
were normalized to the geometric mean of β-actin and β2 microglobulin to obtain Δ cycle 




outcomes.  Data were analyzed this way as opposed to using the ΔΔCt method (21) given the 
lack of a healthy control population and the greater variance that would be introduced using the 
AP group (n=2) as a control.      
Intracellular signaling 
The relative abundance and phosphorylation status of proteins involved in intracellular 
inflammatory and myogenic signaling, as well as muscle protein synthetic and proteolytic 
pathways were determined using Western blot analysis.  Approximately 20 mg of skeletal 
muscle was homogenized in ice-cold lysis buffer with protease and phosphatase inhibitors.  
Supernatant (lysate) was collected following the centrifugation of homogenates (15 min at 
10,000 g at 4°C) to estimate protein concentrations (660 nm Protein Assay; Thermo Scientific, 
Rockford, IL).  Muscle lysates were solubilized in Laemmli buffer, and equal amounts of total 
protein (20 µg) were separated by SDS-PAGE using precast Tris-HCl gels (Bio-Rad).  Proteins 
were then transferred to polyvinylidene fluoride (PVDF) membranes (Bio-Rad) and incubated 
overnight at 4°C with commercially available primary antibodies specific to MyoD and 
Myogenin (Santa Cruz Biotechnology, Santa Cruz, CA), total rpS6 (Abcam, Cambridge, MA), p-
rpS6Ser240/244, total FOXO1, p-FOXO1Thr24, total p38 MAPK, p-p38 MAPKThr180/Tyr182, total 
NFκB p65, p-NFκB p65Ser468, total IκBα, and p-IκBαSer32/36 (Cell Signaling Technology, 
Danvers, MA).  Labeling was subsequently performed using anti-rabbit IgG conjugate with 
horseradish peroxidase (Cell Signaling Technology).  Blots were quantified using ChemiDoc 
XRS (Bio-Rad) and Image Lab software (Bio-Rad) following the application of 
chemiluminescence reagent (Pierce, Rockford, IL).  Heat-shock protein 90 (HSP90) was used to 
confirm equal loading of protein per well.  Total protein normalized to HSP90 and the ratio of 




Isometric quadriceps strength 
A belt-stabilized handheld dynamometer (HHD) (Lafayette Instruments, Lafayette, IN) 
was used to assess isometric quadriceps strength in the injured leg at baseline before surgery and 
at 8 weeks postoperatively.  While isokinetic dynamometry is considered the gold standard for 
strength assessment, this method of handheld dynamometry has been shown to be reliable and 
valid in comparison (22-24).  Using a procedure described by Hansen et al. (22), subjects were 
seated with legs positioned at 90° and thighs stabilized to the table using a standard gait belt.  A 
second gait belt was positioned on the distal third of the tibia and used to stabilize the HHD 
behind the leg of the treatment table.  Five maximal isometric contractions were performed with 
at least 1 minute rest between each contraction.  Subjects were verbally encouraged to push the 
dynamometer with increasing force for 5 seconds during each trial.  The first two trials were 
used as practice, while peak force during the final 3 contractions was averaged for each subject.  
Peak quadriceps isometric strength at week 8 was calculated as a percentage of baseline values.      
Thigh circumference 
Measurements of thigh circumference were used to estimate changes in muscle mass after 
ACL reconstruction.  While muscle volume and cross sectional area (CSA) are generally 
assessed via magnetic resonance imaging (MRI), computerized tomography (CT) scans, or dual 
X-ray absorptiometry (DXA) in research settings, the cost and medical expertise required to use 
this equipment limits access to these measures in clinical practice (25).  Alternatively, 
anthropometric measures (i.e., thigh circumference) are routinely used to roughly estimate 
changes in muscle mass.  Thigh circumference was therefore evaluated during postoperative 
rehabilitation and included as a recovery outcome given that it was part of standard patient care.  




differences between pre-surgery baseline values and measurements at week 2, 4, and 8 were 
calculated.     
Statistical analysis  
Unpaired t-tests were used to examine differences in anthropometric measures, gene 
expression, and protein abundance between patients in the AP (n=2) and OP (n=3) groups.  
Effect sizes were also calculated given the small sample size.  A post hoc power analysis using 
the program G*Power (26) was subsequently conducted to estimate the sample size needed for 
group differences to reach statistical significance at the 0.05 level with power set at 0.80.  
Pearson correlation coefficients were also calculated in a subset of subjects (n=4) to evaluate the 
relationship between intramuscular inflammation and myogenic regulatory factor expression at 
the time of surgery and postoperative muscle recovery outcomes (i.e., thigh circumference and 
quadriceps strength).  As discussed, the patient with an ACL rupture and concomitant meniscal 
root tear was excluded from these analyses given the altered rehabilitation and recovery after 
surgery.  The α level of significance for all statistical tests was two-tailed and set at P < 0.05, 
while trends were noted when 0.05 < P < 0.10.  Data were analyzed using IBM SPSS statistics 
for Windows Version 26 (IBM Corp. Armonk, NY, USA) and are presented as mean ± standard 
deviation (SD) within the text and figures.   
   
Results 
Subjects 
Subject baseline characteristics are shown in Table 3.2.  The 5 male subjects were 29 ± 9 
years old on average and had a mean BMI of 24.9 ± 2.0 which did not differ between groups (P 




Table 3.2  Baseline characteristics for study participants in AP and OP groups  
   AP (n=2)   OP (n=3) 
Age (yr)   29 ± 14  29 ± 7 
Height (m) 1.85 ± 0.0 1.78 ± 0.1 
Weight (kg) 89 ± 7   77 ± 13 
Body mass index (kg/m2) 25.9 ± 2.1 24.2 ± 2.1 
Tourniquet Time (min)   49 ± 42   29 ± 27 
Values mean ± SD.  Baseline characteristics were not different between groups 
 
Dietary Intake 
Pre-surgery dietary intake is summarized in Table 3.3.  Average protein intake derived 
from dietary records was greater in the OP versus AP group (1.9 ± 0.2 g/kg/d OP vs 1.2 ± 0.0 
g/kg/d AP, p = 0.02).  The average caloric intake of 37.4 ± 4.7 kcal/kg/d in the OP group also 
tended to be higher than the 27.3 ± 3.7 kcal/kg/d in AP individuals (p=0.08).  Absolute and 
milligram per kg amounts of the BCAAs (i.e., leucine, isoleucine, and valine) were not different 
between groups (Table 3.4). 
 
Table 3.3  Preoperative absolute, relative, and percent of energy and macronutrient 
intakes for AP and OP groups 
 AP OP p-value 
Absolute     
     Energy (kcal/d)     2415 ± 133 2853 ± 382 0.23 
     Carbohydrate (g/d)       316 ± 46 313 ± 88 0.97 
     Protein (g/d)       104 ± 9 143 ± 19 0.08 
     Fat (g/d)         87 ± 1 110 ± 42 0.51 
Relative    
     Energy (kcal/kg/d)      27.3 ± 3.7 37.4 ± 4.7 0.08 
     Carbohydrate (g/kg/d)        3.6 ± 0.8   4.3 ± 1.7 0.64 
     Protein (g/kg/d)        1.2 ± 0.0   1.9 ± 0.2 0.02 
     Fat (g/kg/d) 1.0 ± 0.1   1.4 ± 0.3 0.14 
Percent Total Energy    
     Carbohydrate (%)         52 ± 5   45 ± 15 0.55 
     Protein (%)         17 ± 2    20 ± 0.2 0.12 
     Fat (%)         33 ± 2 34 ± 9 0.82 







Table 3.4  Preoperative BCAA intake for AP and OP 
 AP OP p-value 
Absolute (g/d)    
     Leucine  6.13 ± 1.37 7.66 ± 1.94 0.41 
     Isoleucine 3.58 ± 1.05 4.33 ± 1.10 0.50 
     Valine  4.13 ± 1.14 5.04 ± 1.27 0.48 
     BCAAs 13.84 ± 3.57  17.04 ± 4.3 0.45 
Relative (mg/kg/d)    
     Leucine 68 ± 10 100 ± 19 0.13 
     Isoleucine 40 ± 9 56 ± 11 0.18 
     Valine 46 ± 9 66 ± 13 0.16 
     BCAAs 154 ± 28  221 ± 42 0.15 







Greater gene expression is indicated by lower ΔCt values.  Muscle MuRF1 expression 
was greater in AP versus OP on the day of surgery (1.10 ± 0.00 vs 1.14 ± 0.01, p = 0.03) (Table 
3.5).  Expression of other genes associated with protein breakdown (MAFbx), myogenesis 
(MyoD, Myogenin, Pax7, Myf5, Myf6) and inflammation (TWEAK, Fn14, TNFα-R, IL6-R) 
were not different between groups (p > 0.05).  Large effect sizes (d > 1.0) were observed for 
TNFα-R, IL6-R, MyoD, and MAFbx.  A post hoc power analysis (assuming 80% power) showed 
that sample sizes would have to increase to 10 to 20 individuals for group differences of these 









Table 3.5.  Gene expression and effect sizes for markers of inflammation, myogenesis, and 
protein breakdown in AP versus OP on day of surgery 
Gene AP  (ΔCt) OP  (ΔCt) p-value 
Effect 
Size 
Sample Size  
Estimate   
Inflammation      
TWEAK 1.17 ± 0.13 1.25 ± 0.01 0.32 0.80 42 
Fn14 1.18 ± 0.02 1.16 ± 0.03 0.60 0.56 102 
TNFα-R 1.14 ± 0.01 1.10 ± 0.02 0.11 2.17 10 
IL6R 1.13 ± 0.00 1.14 ± 0.01 0.23 1.56 16 
Myogenesis 
     
MyoD 1.14 ± 0.02 1.11 ± 0.02 0.33 1.08 18 
Myogenin 1.12 ± 0.06 1.16 ± 0.02 0.35 0.86 46 
Pax7 1.18 ± 0.03 1.17 ± 0.01 0.83 0.18 926 
Myf5 1.20 ± 0.10 1.24 ± 0.02 0.50 0.60 92 
Myf6 1.12 ± 0.03 1.11 ± 0.03 0.77 0.28 416 
Protein Breakdown      
MAFbx 1.05 ± 0.00 1.07 ± 0.02 0.33 1.21 20 
MuRF1 1.10 ± 0.00 1.14 ± 0.01 0.03 3.83 6 
Skeletal muscle mRNA expression of genes associated with inflammation, myogenesis and protein breakdown were 
normalized to the geometric mean of β-actin and β2 microglobulin to obtain Δ cycle threshold (ΔCt) values that are shown as 
mean ± SD for each group 
 
 
Phosphorylation status and total protein content of proteins in inflammatory (NFκB, 
IκBα, p38 MAPK), synthetic (rpS6), and proteolytic (FOXO1) pathways were similar between 
groups (Table 3.6).  There was also no difference between groups in total protein content of 
MyoD and Myogenin.  Large effect sizes were noted for p-NFκB p65 (d = 1.01), p-p38 MAPK 
(d = 1.93) and MyoD (d = 1.37), with corresponding sample sizes of 34, 12, and 20, respectively, 







Table 3.6  Protein expression and effect sizes for markers of inflammation, myogenesis, 
protein synthesis, and protein breakdown in AP versus OP on day of surgery 
Protein AP OP p-value 
Effect 
Size 
Sample Size  
Estimate 
Inflammation      
p-NFκB p65 2.02 ± 0.04 1.58 ± 0.62 0.41 1.01 34 
Total NFκB p65 0.40 ± 0.04 0.71 ± 0.57 0.52 0.77 56 
p-IκBα 0.34 ± 0.31 0.41 ± 0.10 0.74 0.28 394 
Total IκBα  0.61 ± 0.18 0.71 ± 0.37 0.76 0.34 278 
p-p38 MAPK 0.55 ± 0.09 1.07 ± 0.37 0.16 1.93 12 
Total p38 MAPK 1.43 ± 0.20 1.31 ± 0.16 0.51 0.65 78 
Myogenesis      
MyoD 1.97 ± 0.60 2.60 ± 0.22 0.18 1.37 20 
Myogenin 0.98 ± 0.35 1.05 ± 0.35 0.83 0.21 712 
Protein Synthesis      
p-rpS6 1.57 ± 1.31 2.74 ± 1.91 0.51 0.71 64 
Total rpS6 0.52 ± 0.69 0.64 ± 0.94 0.89 0.15 1478 
Protein Breakdown      
p-FOXO1 0.13 ± 0.04 0.35 ±0.43 0.55 0.70 68 
Total FOXO1 0.96 ± 0.14 0.92 ± 0.15 0.77 0.30 364 
 Values mean ± SD 
 
Relationship between inflammation, myogenesis, and recovery outcomes 
A strong correlation was noted between Pax7 expression on the day of surgery and week 
2 quadriceps circumference (Fig. 3.2 A, r = -0.97, p = 0.03).  Week 4 quadriceps circumference 
was also associated with Fn14 expression at the time of ACL reconstruction (Fig 3.2 B, r = 
0.997, p =0.003).  A correlation between TNFα-R expression and week 8 quadriceps 
circumference was also observed (Fig. 3.2 C, r = -0.96, p = 0.04).    
 Quadriceps strength at week 8 was strongly correlated with the expression of Myogenin 
(Fig. 3.4 A, r = -0.99, p = 0.01), Myf5 (Fig. 3.4 B, r = -0.97, p = 0.03), TWEAK (Fig 3.3 C, r = -
0.97, p = 0.03), and p-IκBα (Fig 3.3 A, r = -0.96, p = 0.04).  There was also a trend for the 
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Figure 3.2.  Association of perioperative inflammation and myogenic regulatory factor expression 
with postoperative thigh circumference.  Skeletal muscle mRNA expression of paired box 7 (Pax7) 
(A), fibroblast growth factor-inducible 14 (Fn14) (B), and tumor necrosis factor-α-receptor (TNFα-R) 
(C) were normalized to the geometric mean of β-actin and β2 microglobulin to obtain Δ cycle 
threshold (ΔCt) values.  Note that lower ΔCt values indicate greater gene expression.  Quadriceps 
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Figure 3.3. Association of perioperative muscle inflammation with week 8 quadriceps strength.  
Skeletal muscle mRNA expression of tumor necrosis factor-α-receptor (TNFα-R) (B), and TNF-like 
weak inducer of apoptosis (TWEAK) (C) were normalized to the geometric mean of β-actin and β2 
microglobulin to obtain Δ cycle threshold (ΔCt).  Note that lower ΔCt values indicate greater gene 
expression. p-IκBα protein abundance (A) is shown relative to Total IκBα.  Week 8 quadriceps peak 
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Figure 3.4.  Association of perioperative myogenic regulatory factor expression with week 8 
quadriceps strength.  Skeletal muscle mRNA expression of Myogenin (A) and myogenic factor 5 
(Myf5) (B) were normalized to the geometric mean of β-actin and β2 microglobulin to obtain Δ cycle 
threshold (ΔCt) values.  Note that lower ΔCt values indicate greater gene expression.  Week 8 






The current study assessed the influence of protein intake on perioperative inflammatory 
and myogenic signaling in vastus lateralis muscle, and if these signaling pathways were related 
to postoperative muscle recovery outcomes.  Lower expression of static markers of proteolysis in 




these individuals  While markers of inflammation and myogenesis were not different between 
groups, a post hoc power analysis suggests sample sizes likely limited significance of these 
results.  Most notably, inflammation and myogenic regulatory factor expression at the time of 
surgery are seemingly associated with postoperative thigh circumference and quadriceps strength 
during postoperative rehabilitation.     
Bamman et al. (15) were the first to suggest that muscle inflammation at the time of 
surgery may influence postoperative recovery outcomes after identifying a state of heightened 
basal proinflammatory signaling in muscle surrounding the diseased hip of some total hip 
arthroplasty (THA) patients.  Dichotomizing patients using median expression of the TWEAK 
receptor fibroblast growth factor-inducible 14 (Fn14) into groups considered susceptible 
(MuIS(+); high Fn14 expression) or not susceptible (MuIS(-); low Fn14 expression) to excessive 
muscle inflammation revealed MuIS(+) individuals had heightened expression of all 
inflammatory genes evaluated (e.g., TNFα, IL-6, TWEAK) and decreased muscle protein 
synthesis (MPS) in muscle surrounding the diseased hip.  The heightened inflammatory signaling 
and changes in MPS in the MuIS(+) versus MuIS(-) group would be expected to limit 
postoperative recovery by reducing muscle regenerative capacity and inducing muscle atrophy.  
Heighted inflammatory cytokine expression in muscle surrounding the knee after ACL injury 
may similarly limit postoperative muscle recovery potential.  Attenuating intramuscular 
inflammatory signaling prior ACL reconstruction may therefore protect muscle mass and 
enhance recovery in the postoperative period. 
 Dietary protein intake was considered as a countermeasure to excessive skeletal muscle 
inflammation in the current study given the hypothesized antioxidant potential of BCAAs.  




protection and attenuate oxidative-stress related inflammatory signaling given these amino acids’ 
role as precursors for the intracellular antioxidant glutathione (GSH) (18).  Treating C2C12 
muscle cells with BCAA-rich whey protein, for example, increased GSH levels by 25.7 % and 
138% at low and high concentrations, respectively (19).  Dietary protein may also modulate 
satellite cell dynamics directly by increasing their activity (i.e., number proliferating cells) (27, 
28) and abundance (16, 17).  We therefore hypothesized that dietary protein intake of 2.0 versus 
1.0 g protein·kg-1·d-1 for two weeks prior to ACL reconstruction would optimize postoperative 
recovery potential by attenuating inflammation and promoting satellite cell abundance and/or 
activity.   
 In contrast to study hypotheses, inflammation and myogenic regulatory factor expression 
were not different between groups in the current study.  Low statistical power due to the small 
sample size (n=5) may have limited significance of these results.  A large effect size (d > 1.0) 
was noted for gene expression of TNFα-R, IL6-R, and MyoD and for protein abundance of p-
NFκB p65, p-p38 MAPK, and MyoD.  A post hoc power analysis (power set at 0.80) revealed 
that a total sample size of 10 to 18 subjects would be needed (n=34 for p-NFκB p65) for group 
differences of these inflammatory and myogenic markers to reach statistical significance at the 
0.05 level.  The possibility exists that a significant treatment effect would have been observed 
with a larger sample size.  Insignificant findings may also be due to the diet intervention itself.  
Prescribing higher protein intake and incorporating beef into meals of the OP diet was intended 
to provide a greater abundance of dietary EAAs (BCAAs in particular) versus what was 
consumed in the AP group.  The lack of differences in absolute and relative amounts of BCAAs 
between AP and OP individuals may be why the proposed effect of these amino acids on 




 While inflammatory and myogenic signaling appear unaltered by different levels of 
protein intake, the intervention may have attenuated muscle protein breakdown (MPB) in the OP 
group.  Kim et al. (29) have shown that a greater whole body net protein balance following 
consumption of a high (70 g) versus moderate (40 g) protein meal can be attributed to a larger 
reduction in protein breakdown with the 70 g dose.  They hypothesized that greater protein 
intake and the associated abundance of exogenous amino acids reduced the reliance on protein 
breakdown to provide amino acid precursors for sustaining protein synthesis.  Additional work 
from our laboratory hypothesized that an observed decrease in post-exercise fractional synthetic 
rate following a habitual increase in dietary protein intake was due to an abundance of free 
amino acids that attenuated proteolysis during exercise (30).   
Expression of the muscle-specific ubiquitin ligases muscle ring finger 1 (MuRF1) and 
muscle atrophy F-box (MAFbx)/atrogin-1 were evaluated in the current study to give some 
insight into whether higher protein intakes influenced MPB.  Muscle MuRF1 expression was 
greater in AP versus OP individuals on the day of surgery (p = 0.03), suggesting an abundance of 
exogenous amino acids in the OP group may have attenuated breakdown in the fasted state 
during ACL reconstruction. Although a similar effect was not significant for MAFbx, the 
calculated effect size (d = 1.21) and subsequent power analysis revealed a sample size of 20 
would be needed for the group difference to reach statistical significance at the 0.05 level.  While 
these findings suggest breakdown was lower in the OP group, this must be interpreted with 
caution given that average caloric intake relative to body weight tended to be higher (p=0.08) in 
the OP versus AP group suggesting the alterations in proteolytic gene expression may not be the 




 Although MPB appeared lower during surgery in OP versus AP individuals, 
postoperative changes in thigh circumference and strength were not different between groups 
(data not shown).  Extending the Bamman et al. (15) proposal that inflammation at the time of 
surgery dictates regenerative capacity and postoperative recovery, we evaluated whether 
perioperative markers of inflammation and myogenesis were associated with recovery outcomes 
after ACL reconstruction.  We admit that the small sample size (n=4) and correlative nature of 
this analysis are limitations and consider the findings preliminary and meriting future work.  
Regardless, lower expression of the myogenic regulatory factor Pax7 and higher levels of Fn14 
at the time of surgery were associated with a greater loss of thigh circumference at week 2 and 
week 4, respectively.  Indeed, these findings correspond with the Bamman study (15) that 
suggested greater Fn14 expression in TKA patients would decrease regenerative capacity and 
limit postoperative recovery potential.  In contrast to what was expected, higher levels of TNFα-
R at the time of surgery were associated with greater thigh circumference at week 8.  This 
contradictory finding may reflect the dual roles of inflammatory signaling in both promoting (31) 
and inhibiting (11) myogenesis, or may be a result of the time elapsed from surgery.  Disuse in 
the early postoperative period (< 1 month) leads to a loss of muscle mass that is subsequently 
restored as rehabilitation incorporates more intense exercises and workloads.  By two months 
post-ACL reconstruction in the current study, thigh circumference was increased above baseline 
values in two subjects while deficits persisted in the other two.  Although this divergent response 
to rehabilitation may be related to TNFα-R expression at the time of surgery, it’s possible that 
other factors such as training status or gains in fat mass influence changes in thigh circumference 




 Perioperative markers of inflammation and myogenesis were also associated with 
quadriceps strength at week 8.  Individuals with lower expression of the myogenic regulatory 
factors myogenin and Myf5 at the time of surgery, for example, had less quadriceps strength at 
week 8 relative to baseline values.  Greater day of surgery expression of TNFα-R and p-IκBα, a 
regulator of pro-inflammatory NFκB signaling, was also associated with lower quadriceps 
strength at week 8 relative to baseline.  These findings collectively suggest that heightened 
intramuscular pro-inflammatory signaling and a corresponding downregulation of myogenic 
regulatory factor gene expression at the time of surgery are associated with negative functional 
outcomes postoperatively.  TWEAK expression does not follow this pattern, however, as 
increased expression of this cytokine was associated with greater week 8 strength relative to 
baseline.  Although this may reflect the divergent roles of this cytokine in both stimulating (32) 
and inhibiting (8, 10) myogenesis, it also appears that this correlation is driven by one outlier.  
Expression of TWEAK and quadriceps strength are both greater for 1 person, however, TWEAK 
expression was the same for the other three subjects despite differences in strength.   
 In conclusion, observing a significant effect of preoperative protein intake on muscle 
inflammation and myogenic regulatory factor expression was likely limited by the small sample 
size (n=5).  Protein breakdown, however, did appear attenuated at the time of surgery in the OP 
group.  While it’s possible this would protect muscle mass in OP individuals, thigh 
circumference or strength were not different between groups in the postoperative period.   
Greater inflammatory cytokine expression and diminished markers of myogenesis at the time of 
surgery were generally associated with a greater loss of thigh circumference and lower strength 




inflammation and regenerative capacity are associated with postoperative muscle recovery 
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Optimal protein and feeding strategies to accelerate muscle mass and functional recovery 




Anterior cruciate ligament (ACL) injury and subsequent surgical reconstruction disrupts 
normal limb function and mobility.  The associated decline in activity and deficits in 
neuromuscular signaling induce a rapid loss of muscle mass (i.e., disuse atrophy) and function 
given the unloading and reduced neural activation of muscle.  Disuse-related muscle atrophy and 
weakness following ACL injury and reconstruction can be challenging to overcome, and often 
persists after physical rehabilitation efforts (1).  Failing to reverse these deficits in muscle mass 
and functional capacity may limit activities of daily living, physical performance, and quality of 
life.  Developing strategies to attenuate muscle atrophy and preserve muscle function with disuse 
are therefore necessary to accelerate and optimize recovery from ACL reconstruction.   
Muscle mass is regulated by rates of muscle protein synthesis (MPS) and muscle protein 
breakdown (MPB) that fluctuate throughout the day in response to feeding and fasting.  A 
persistent negative net balance (MPS < MPB) resulting from declines in MPS and a possible 
early increase in MPB underlies decreases in muscle mass during conditions of disuse (2).  
Interventional strategies designed to attenuate this decline in MPS (postabsorptive and 
postprandial) and possible early increase in MPB would therefore protect muscle mass under 
disuse conditions.  Manipulating the amount and quality of protein consumed has been studied in 
experimental models of disuse (i.e., bed rest and immobilization in healthy individuals) as a way 
to increase the anabolic response to protein ingestion, overcome deficits in postprandial MPS, 




conditions after orthopedic surgery that are also accompanied by some muscle activation during 
postoperative rehabilitation.  Given that exercise sensitizes skeletal muscle to the anabolic effect 
of protein ingestion (7), early rehabilitation may act synergistically with a protein-based 
intervention to overcome disuse-related deficits in protein turnover and protect muscle mass.  
The synergistic effect of physical rehabilitation (i.e., resistance exercise) and protein intake on 
increasing MPS may result in net muscle protein accretion and hypertrophy of muscle when 
performed habitually.       
Research focused on the synergistic effect of exercise and protein intake on rates of MPS 
generally implements resistance exercise at workloads much greater than what is possible after 
injury.  Whether the body weight or light-load resistance exercise and electrical stimulation of 
muscle during early rehabilitation has a stimulatory effect on rates of MPS or improves anabolic 
sensitivity to protein ingestion is not completely understood.  Whether standard rehabilitation 
combined with a protein-based diet intervention would attenuate disuse atrophy and accelerate 
recovery of muscle mass and function in the postoperative period after ACL reconstruction is 
unclear.  This case study characterizes changes in quadriceps strength and thigh circumference of 
the injured and non-injured leg during standard rehabilitation from ACL reconstruction in a 
patient consuming ~2.0 g protein·kg-1·d-1.  The aim of this preliminary study is to aid in the 
development of future research and the design of optimal protein-based diet interventions to 
attenuate muscle atrophy and weakness and accelerate recovery outcomes after musculoskeletal 
injury or orthopedic surgery.       
Patient overview and surgery details 
The patient was a 27 year old male undergoing his first ACL reconstruction surgery.  He 




cardio exercise twice a week (30 – 60 mins) before the injury.  The patient had his ACL 
reconstructed using a bone-tendon-bone (BTB) autograft 36 days after the injury occurred.  He 
was initially anesthetized with propofol and then maintained with inhalation anesthetic 
(sevoflurane) during surgery.  The patient also received an adductor canal and geniculate nerve 
block using 0.25% Marcaine with 1:200,000 epinephrine.  A pneumatic tourniquet was placed 
‘as-high-as-possible’ on the thigh of the injured limb during sterile preparation and draping, and 
inflated to 250 mm Hg prior to incision and until the graft was harvested (~14 minutes).   
Postoperative rehabilitation 
 The patient used crutches and his knee was immobilized in a leg brace locked at ~0° of 
flexion until the first postoperative visit with the physician (< 7 days).  The patient was then 
cleared to progress with weight bearing as tolerated (WBAT) and to attend twice weekly 
physical therapy.  All rehabilitation was done with measures of progress performed by by the 
same physical therapy assistant and following the Orthopedic Associates of Hartford return-to-
sport after ACL reconstruction protocol (Appendix I) and phase-specific exercises (Appendix 
II).  Initial rehabilitation focused on controlling pain, reducing swelling and restoring normal 
range of motion.  An early emphasis on WBAT, isometric exercises, and electrical stimulation of 
muscle through neuromuscular electrical stimulation (NMES) was also done to facilitate the 
return of normal neuromuscular signaling.  Rehabilitation then shifted to incorporate progressive 
resistance exercise (i.e., body weight then higher loads) after neuromuscular control and range of 
motion was restored.  Plyometric and agility exercises were also incorporated into later phases of 






Table 4.1  Overview of the postoperative ACL rehabilitation protocol 




Restore knee extension, gradually increase knee flexion 
to 90°; diminish pain and swelling; restore patellar 
mobility; reestablish quadriceps control; improve 
ambulation to full weight bearing. 
 
Maintain knee extension; gradually increase knee 
flexion to 110°-120°; diminish pain and swelling; 
maintain patellar mobility; restore proprioception; 
increase muscular training. 
Exercises: • Ankle pumps 
• Ankle resistance band exercises 
• Quadriceps and gluteal set exercises 




• OKC knee extension (90°- 40°, no weight) 
• Quadriceps isometrics  (no weight) 
• Single leg raises 
• Front and lateral step-ups 
• Lateral step overs 
• Mini squats (0°-30° flexion, DL, BW) 
• Leg press (DL, sub-maximal) 




Quadriceps strength to >75% of non-injured leg; 
restore knee ROM to 0°-125°; improve lower extremity 
strength and endurance; enhance proprioception and 
neuromuscular control. 
 
Quadriceps strength to >80% non-injured  
leg; restore full knee ROM, normal gait pattern; 
continue to improve lower extremity strength balance, 
proprioception, neuromuscular control, and muscular 
endurance. 
Exercises: • OKC knee extension (90°- 40°, no weight) 
• Quadriceps isometrics (no weight) 
• Single leg raises 
• Front and lateral step-downs 
• Lateral step overs 
• Mini Squats (0°-50° flexion, DL) 
• Leg press (DL and SL, increasing resistance) 
• Perturbation training (DL and SL) 
• Eccentric exercises 
• Core strengthening 
• Progress intensity and duration of exercise 
performed in the previous phase 
• Squats (DL and SL, internal and external cues) 
• SL anterior reach 
• Plyometric leg press 
• Progress step-down and lateral step exercises with 
resistance bands 
• Bridges with knee extension (DL and SL) 
• Anterior and lateral lunges 
• Perturbation training 
• Eccentric exercises 




Quadriceps strength to <15% difference between legs; 
increase muscle power, endurance and neuromuscular 
control; begin selected skill drills.   
 
Exercises: • Progress intensity and duration of exercises  
performed in the previous phase 
• Squats (DL and SL, internal and external cues) 
• Lateral and forward squat walks with resistance 
band 
• Side and prone planks (with leg raises) 
• Plyometric training protocol 
• Begin walk-to-run protocol 
• Eccentric exercises 
• Agility exercises 
 
Anterior cruciate ligament (ACL), body weight (BW), double leg (DL), neuromuscular electric stimulation (NMES), open 




 Diet intervention 
 The patient’s energy requirements were established relative to estimated resting energy 
expenditure (Harris-Benedict equation), estimates of energy intake, and level of physical activity 
reported at baseline.  This information was used to develop a 1-week, eucaloric (i.e., weight 
maintenance) cycle menu that provided 2.0 g protein·kg-1·d-1, 30% of energy intake from fat, and 
remaining calories from carbohydrates.  The diet intervention also incorporated 5 servings (3 oz) 
of beef per week as a high quality protein source (see Table 4.2 for example day).  The patient 
followed this prescribed diet 2 weeks prior to ACL reconstruction and continued the diet 
intervention for 16 weeks postoperatively.  A post-rehabilitation supplement was also integrated 
into the overall diet design (see Table 4.2 for example day).  The patient consumed 1 serving 
(~27.4 g) of IsoPrime BeefTM directly after each physical therapy appointment.  The 
macronutrient and amino acid composition of the supplement was the same as previously 
reported in Chapter 3 (Table 3.1).   
 
Table 4.2 Example of dietary meal plan provided to patient  




1 bagel with 2 Tbsp. of nut butter, 





1 bagel with 2 Tbsp. of cream cheese, 2 
oz. turkey sausage, 8 oz. lemonade 
Morning 
Snack 
5 Triscuit crackers, ¾ cup of 2% 
 cottage cheese 
Morning 
Snack 
1 large apple with 2 Tbsp. of peanut 
butter, 2/3 cup of low-fat flavored 
yogurt 
Lunch 1 spicy black bean burger with 1 slice 
of cheese on spinach tortilla, 1 cup  
of baby carrots, 8 oz. lemonade 
Lunch 1 large tortilla wrap, 1/3 cup hummus, 1 
cup assorted non-starchy vegetables, 1 
cup of baby carrots with 1 Tbsp. of 
ranch on the side, ½ cup of apple sauce 
Dinner 3 oz. of grilled sirloin tips, 1 cup  
of rice, ½ cup cooked green beans 
After 
Rehabilitation  




2/3 cup low-fat flavored yogurt,  
1 banana  
Dinner Fajita – two 8-inch tortilla wraps, 4 oz. 
of cooked chicken, 1 cup of cooked 





 The patient recorded his food intake for 7 days beginning 1 week prior to surgery, and 
again at 4, 8, 12, and 15 weeks postoperatively.  Nutritionist ProTM software (Axxya Systems, 
LLC, Woodinville, WA) was used to analyze these food records and estimate total energy, 
carbohydrate, fat, and protein intake levels, as well as branched chain amino acid content of the 
diet.  Average daily energy intake for the duration of the diet intervention was approximately 
2500 calories provided by ~2.1 g protein·kg-1·d-1, ~4.2 g carbohydrate·kg-1·d-1, and ~32% of 
total energy from fat (Table 4.3).  The patient consumed about 8.6 g of leucine, 4.8 g isoleucine, 
and 5.6 g of valine per day.   
  
 
Table 4.3  Dietary intake before surgery and for the duration of the rehabilitation intervention  
 Pre Wk 4 Wk 8 Wk  12 Wk 15 Average 
Absolute        
     Energy (kcal/d) 2422 2396 2468 2856 2383 2505 ± 198 
     Carbohydrate (g/d) 322 297 281 298 272 294 ± 19 
     Protein (g/d) 122 121 134 198 143 144 ± 32 
     Fat (g/d) 81 90 104 77 84 87 ± 11 
Relative       
     Energy (kcal/kg/d) 37.7 38.0 37.5 37.2 37.2 37.5 ± 0.3 
     Carbohydrate (g/kg/d) 4.7 4.4 4.1 4.3 3.9 4.2 ± 0.3 
     Protein (g/kg/d) 1.8 1.8 2.0 2.9 2.1 2.1 ± 0.4 
     Fat (g/kg/d) 1.5 1.8 2.3 1.8 1.8 1.9 ± 0.3 
Percent Total Energy       
     Carbohydrate (%) 53 50 46 42 46 47 ± 4 
     Protein (%) 20 20 22 28 24 23 ± 3 
     Fat (%) 30 34 38 24 32 32 ± 4 
Averages are mean ± SD    
 
Outcomes of the optimal protein and rehabilitation intervention 
 Thigh circumference was measured at baseline and weeks 2, 4, 8, 12, and 16 
postoperatively.  Quadriceps strength was also evaluated at baseline before surgery and weeks 8, 




as previously discussed in Chapter 3.  Body weight was also measured and recorded by the 
patient once a week at approximately the same time, after using the restroom, before eating or 
drinking, and with minimal or no clothing.        
Thigh Circumference 
 Changes in thigh circumference are shown in Figure 4.1.  Thigh circumference of the 
injured leg decreased from baseline by approximately 1 cm at 2 weeks postoperatively in the 
injured leg, and was 1.7 cm less than the non-injured leg at this time point.  Injured-leg thigh 
circumference was similar to baseline and the non-injured leg by week 4.  Values progressively 
increased after week 4 in both legs such that thigh circumference was ~3.8 and 3.9 cm greater at 































Figure 4.1 Changes in thigh circumference for the duration of diet and rehabilitation intervention 




Peak isometric quadriceps force decreased by 26 lb at week 8 compared to baseline in the 




lower and similar to week 8.  In contrast, peak force of the non-injured leg increased at each time 
point and was 47.8 lb greater at week 16 versus baseline.  
 

























    
Figure 4.2 Changes in quadriceps strength for the duration of the diet and rehabilitation 




 The subject’s initial weight was 148.4 pounds which increased by 6.2 pounds to 154.6 at 
week 15.   
 
Discussion 
While protein-based diet interventions have demonstrated the capacity to protect muscle 
mass and/or function in experimental models of disuse (i.e., immobilization and bed rest in 
healthy individuals) (3-6), this concept has rarely been considered in the context of disuse 
following musculoskeletal injury or orthopedic surgery.  The purpose of this case study was to 
characterize changes in quadriceps strength and thigh circumference after ACL reconstruction in 




gains in injured-leg thigh circumference suggest the diet intervention may have benefited 
recovery outcomes by attenuating disuse atrophy and potentiating muscle hypertrophy during 
postoperative rehabilitation.  The progressive increase of thigh circumference and quadriceps 
strength in the non-injured leg also indicates that rehabilitation combined with a diet providing 
2.0 g protein·kg-1·d-1 has the capacity to promote gains in muscle mass and strength.   
Muscle atrophy and weakness occurs rapidly after ACL reconstruction due to injury-
related deficits in neuromuscular signaling as well as protective measures implemented to avoid 
further injury (i.e., immobilization and reduced activity).   Quadriceps CSA 16 days post-ACL 
reconstruction in a group of young patients, for example, was 13.1% lower in the operative leg 
compared to baseline (8).  Quadriceps CSA similarly decreased by 20% during an 11 day 
postoperative period in another study (9).  The loss of thigh circumference observed at week 2 in 
this case study suggests this patient also experienced a rapid loss of muscle mass in the early 
postoperative period.  The 1.7 cm difference in thigh circumference between legs at week 2 was 
greater than any other time point.  While this difference seems small, anthropometric 
assessments of whole thigh circumference may be limited in accurately determining muscle 
losses consequent to quadriceps atrophy.  Young et al. (10) found that a 2.5 cm difference in 
thigh circumference between injured and non-injured limbs corresponded with an approximately 
22-33% lower quadriceps cross sectional area (CSA), suggesting that even subtle differences in 
thigh size can represent a substantial loss of quadriceps mass (11).  When interpreting these 
findings, however, it must be noted that non-injured leg thigh circumference was 2 cm greater at 
two weeks versus the pre-surgery baseline value.  This is may be due to a measurement error at 
baseline given the similarity between week 2 and week 4 measures (43.7 versus 43.4 cm), the 




 Injured-leg thigh circumference was restored and similar to the non-injured leg four 
weeks after surgery.  Thigh circumference also increased during later phases of rehabilitation 
(i.e., weeks 8, 12, and 16), and was surprisingly ~1 cm greater in the injured versus non-injured 
leg at 12 and 16 weeks.  These findings contrast literature reporting deficits in injured-leg muscle 
mass that persist during and after physical therapy.  Andrade et al. (12), for example, reported a 
smaller thigh circumference in the injured versus uninjured limb (46.9 ± 4.3 vs. 48.5 ± 3.9 cm, p 
< 0.01) at 4 months post-ACL reconstruction.  Quadriceps CSA was similarly 15% lower in the 
injured versus uninjured leg 6 months postoperatively in another ACL patient population (1).   
One explanation for this patient’s unexpected return of thigh circumference in the injured 
leg and increased thigh size in both legs during postoperative rehabilitation may be the diet 
intervention (i.e., the patient’s habitual consumption of higher dietary protein in the context of 
energy balance).  Disuse-related muscle atrophy after ACL reconstruction can be attributed to a 
decline in MPS (postabsorptive and postprandial) and a possible early increase in MPB (2, 13).  
Improving the anabolic response to protein ingestion by manipulating the amount and quality 
(i.e., essential amino acid and leucine content) of protein consumed has been proposed as a way 
to overcome deficits in postprandial MPS and preserve muscle mass during disuse conditions.  
Protein intake at the higher end of clinical recommendations may act synergistically with 
exercise performed during rehabilitation to increase MPS and promote muscle protein accretion 
when repeated over time.   
While literature translating this concept to practice is limited, protein-based interventions 
do appear to benefit outcomes following orthopedic surgery.  Supplementing the diet with 
essential amino acids (EAAs) after total knee arthroplasty, for example, attenuated the 




the anabolic potential of the dietary protein through leucine supplementation also led to greater 
improvements in thigh circumference (measured 10 cm from the patella) during later phases of 
rehabilitation after ACL reconstruction (16).  These findings suggest that the high quality 
protein-based diet intervention providing ~2.0 g protein·kg-1·d-1 during this patient’s 
postoperative rehabilitation may have similarly attenuated muscle loss and potentiated gains in 
muscle mass leading to the observed increase in thigh circumference.  The simultaneous and 
consistent consumption of adequate energy also contributes to optimal protein utilization.       
While the diet intervention in this case study appeared to protect muscle mass 
postoperatively, the benefit did not extend to strength outcomes.  Deficits in injured-leg strength 
were observed at all postoperative time points.  Although these findings are consistent with 
previous research showing knee extension strength is diminished at three (17), four (18) and six 
(1, 17, 18) months post-ACL reconstruction, it’s notable that quadriceps strength deficits 
persisted in this patient despite the increase in thigh circumference.  The attending physical 
therapist noted the patient’s apprehension specific to the injured leg during testing at week 16 
and greater pain levels compared to previous testing.  This may explain why strength was 
restored at week 12 but then decreased again at week 16.  It is possible the diet intervention 
would have benefited the restoration of strength at time points later than what were evaluated in 
the current case report.  Future research should consider the effect of a protein-based intervention 
on strength outcomes during early activity and return-to-sport phases of rehabilitation (> 4 
months postoperatively).    
This case study provides insight into the anabolic potential of exercise during 
rehabilitation combined with a protein-based diet intervention.  The synergistic effect of 




workloads much greater than what is possible in the postoperative period after ACL 
reconstruction.  Whether body weight and light-load resistance exercise performed during 
rehabilitation has a stimulatory effect on rates of MPS or improves the anabolic response to 
protein ingestion is not fully understood.  While strength was not restored in the injured leg in 
this patient, quadriceps peak force was increased substantially at week 16 compared to baseline 
in the non-injured leg (85.7 lb vs. 47.9 lb).  Non-injured leg thigh circumference also 
progressively increased at each postoperative time point.  This is consistent with previous 
literature in healthy young men showing 12 weeks of very light load resistance exercise (i.e., 
16% of 1-repetition maximum) followed by intake of a protein-containing nutrient supplement 
led to a 3% hypertrophy of the quadriceps muscle (19).  Findings in this individual suggest that 
rehabilitation acts as a ‘resistance training’-type stimulus that, when combined with a diet 
providing 2.0 g protein·kg-1·d-1, can lead to gains in muscle mass and strength. 
Observations for this case study must be interpreted with caution given the use of thigh 
circumference to estimate changes in muscle mass.  While the implemented diet intervention was 
designed for weight maintenance (i.e., ± 5 lbs.), it is well noted that increases in body weight and 
lean body mass accompany strength training interventions.  However, thigh circumference 
measures cannot differentiate the individual contributions of muscle mass and subcutaneous fat 
to total thigh size.  Given the 6.2 pound increase in body weight from pre-surgery to 
postoperative week 16, the observed increase in this patient’s thigh circumference may reflect 
alterations in leg fat mass.  Future work with larger populations should use DXA, magnetic 
resonance imaging (MRI), or computed tomography (CT) scans to evaluate changes in muscle 




strength should also be considered in future work given that quadriceps peak force was not 
restored at week 16.   
Despite these limitations, this case study provides preliminary evidence consistent with 
scientific literature and suggests a protein-based diet intervention in the postoperative period 
after ACL reconstruction may protect muscle mass in the injured leg.  The progressive increase 
in thigh circumference and quadriceps strength in the non-injured leg also indicates that physical 
rehabilitation is analogous to resistance exercise in promoting gains in muscle mass and strength, 
particularly when combined with a diet providing 2.0 g protein·kg-1·d-1.  Future research is 
warranted on the role of nutrition, higher protein intakes specifically, during physical 
rehabilitation following orthopedic surgery for optimizing muscle mass, strength, and function 
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Testosterone supplementation upregulates myogenesis and attenuates proteolytic gene 





 The effects of exogenous testosterone administration on lean body mass accretion are 
well-documented (1-3), and suggest testosterone supplementation may be a viable strategy for 
preserving muscle mass and functional outcomes in healthy populations exposed to extreme 
stress.  US military personnel, in particular, are subjected to extreme stressors during training 
and combat operations.  High physical demands, sleep deprivation, and sustained periods of 
severe, unavoidable energy deficit lead to a loss of lean body mass that, in some cases, cannot be 
overcome by manipulating dietary protein intake alone (4-6).  Losses in lean body mass under 
these conditions generally occur with a concomitant suppression of the hypothalamic-pituitary-
gonadal axis (7, 8), and may therefore be attenuated with supplemental testosterone (9, 10).   
The anabolic effects of supplemental testosterone have been attributed to a modulation of 
pathways regulating muscle protein synthesis and breakdown (11) as well as satellite cell and 
muscle pluripotent stem cell commitment and differentiation (12, 13).  Upregulation of anabolic 
signaling through the mechanistic target of rapamycin (mTOR) pathway (14) and 
downregulation of ubiquitin proteasome-mediated proteolysis (15) has been observed in vitro 
following testosterone administration in cultured muscle cells.  A persistent increase in muscle 
protein synthesis (MPS) and decrease in muscle protein breakdown (MPB) would lead to lean 
mass accrual over time.  Testosterone-mediated increases in the fusion of activated satellite cells 




Activation, proliferation, and differentiation of normally quiescent muscle satellite cells and 
pluripotent stem cells in response to the sequential expression of specific transcription factors 
(i.e., Pax7, Myf5, MyoD, myogenin, MRF4) generates new multinucleated myotubes.  
Testosterone supplementation in humans has been shown to increase the number of proliferating 
satellite cells and expression of myogenin, indicating testosterone promotes cell cycle entry and 
later stages of myogenesis (12).  Testosterone-mediated increases in satellite cell number and 
their fusion with existing fibers may be regulated through androgen receptor-independent (17), 
and dependent pathways (13, 18, 19), or through a modulation of upstream pro-inflammatory 
signaling (20-22).  Without question, there are a number of potential mechanisms by which 
testosterone supplementation may mediate changes in muscle mass.        
To our knowledge, the molecular impacts of exogenous testosterone administration 
during severe exercise- and diet-induced energy deficits remain unexplored.  Understanding the 
effect of testosterone on intracellular signaling pathways regulating muscle mass under these 
conditions will facilitate the development of androgen-related therapies for mitigating muscle 
losses during situations of extreme operational stress.  The objective of this study was therefore 
to examine mTOR-mediated anabolic signaling, ubiquitin proteasome-mediated proteolysis, and 
intracellular markers of myogenesis following 28 days of a severe diet- and exercise-induced 
energy deficit (~55% deficit) with testosterone supplementation (200 mg testosterone 
enanthate/wk) or a placebo.  Androgen receptor and markers of inflammation were examined as 
potential upstream regulators of these signaling pathways.  Analysis of muscle protein and gene 
expression was done following a 14-day weight maintenance period and a 28-day energy deficit 
under fasted, rested conditions and in recovery from exercise and a protein-containing meal.  We 




androgen receptor expression and intramuscular inflammation to upregulate myogenic and 
anabolic (i.e., mTOR) signaling pathways, and decrease proteolysis relative to weight 
maintenance and 2) the magnitude of this response would be associated with changes in lean 




Participants were part of a larger proof-of-concept, single centre, randomized, double-
blind, placebo-controlled trial that assessed the effects of exogenous testosterone administration 
on changes in body composition with 28 days of a severe exercise- and diet-induced energy 
deficit (10).  Participant eligibility and recruitment details have been reported previously (9).  
Briefly, 50 young (18–39 y), physically active (≥ 2-d/wk aerobic and/or resistance exercise) men 
who met age-specific US Army body composition standards (23) and had total testosterone 
concentrations within the normal physiological range (10.3-34.7 nmol/dL) were recruited locally 
from the Baton Rouge, LA area.  Data in this chapter are presented for 20 of those 50 
participants to characterize the intracellular response mediating the greatest gains (TEST, n=10) 
and reductions (PLA, n=10) in leg lean mass during energy deficit.  This study was approved by 
the Institutional Review Board at the Pennington Biomedical Research Center (PBRC, Baton 
Rouge, LA) and by the Human Research Protection Office of the US Army Medical Research 
and Material Command (Ft. Detrick, Fredericksburg, MD).  All participants provided written, 







Figure 5.1.  Experimental design.  The current analysis was part of a larger study assessing the effects of 
exogenous testosterone administration on changes in body composition after a 28-day diet- and exercise-
induced energy deficit designed to be 45% of total energy needs.  Muscle biopsies were collected 
following weight maintenance (WM) and energy deficit (ED) at baseline (Base), 1 h after 60 min of cycle 
ergometry (Post), and an additional 5 hours into recovery (Rec) from exercise after a protein-containing 
meal.  Steady-state aerobic exercise bouts were matched between WM and ED for each participant based 
on power output (124 ± 22 W) and total work performed (448 ± 77 kJ).       
 
Experimental design 
This study involved 14 days of weight maintenance (WM) followed by 28 days of a highly 
controlled exercise- and diet-induced energy deficit (ED) (Fig. 5.1).  Skeletal muscle 
inflammatory, myogenic, synthetic, and proteolytic signaling pathways were assessed in vastus 
lateralis biopsies following WM (d 14) and energy deficit (d 42) at baseline and in response to 
exercise and a protein-containing meal.  Participants maintained their habitual physical activity 
and began a controlled, eucaloric diet providing 1.6 g protein·kg-1·d-1, 30% energy intake from 
fat, and remaining calories from carbohydrates during the 14-day, free-living WM phase.  
Energy requirements for weight maintenance were individualized using the Mifflin St Jeor 
Equation with an activity factor of 1.3, as well as 7-day accelerometer and 3-day activity log data 




verified by research dietitians, accelerometry, and measuring semi-nude body weight daily with a 
calibrated digital scale (GSE Inc. Model 450, GSE Scale Systems, Novi, MI) after an overnight 
fast and morning void (10).  Body mass was stable (d 0, 75.6 ± 13; d 14 75.3 ± 13) and dietary 
intake was similar in both groups during WM (Table 5.1).    
 
Table 5.1.  Dietary intake during weight maintenance and energy deficit in TEST versus PLA 
 TEST (n=10)   PLA (n=10) 
 WM ED WM ED 
Absolute intake  
     Energy (kcal/d)     2650 ± 131   1784 ± 314      2574 ± 340    1707 ± 268 
     Carbohydrate (g/d)       344 ± 52     190 ± 39      340 ± 54        188 ± 45 
     Protein (g/d)       132 ± 25     128 ± 24        121 ± 15      117 ± 16 
     Fat (g/d)         88 ± 13       60 ± 11          86 ± 11        57 ± 9 
Relative Intake     
     Energy (kcal/kg/d)       33.5 ± 3.1     25.0 ± 4.0       36.5 ± 3.1     24.0 ± 4.0 
     Carbohydrate (g/kg/d)        4.4 ± 0.5      2.7 ± 0.5         4.9 ± 0.9       2.6 ± 0.6 
     Protein (g/kg/d)        1.7 ± 0.1      1.8 ± 0.3       1.70 ± 0.1       1.6 ± 0.2 
     Fat (g/kg/d        1.1 ± 0.1      0.8 ± 0.1         1.2 ± 0.1       0.8 ± 0.1 
Values are presented as mean ± SD.  Independent sample t tests were used to compare testosterone 
(TEST) and placebo (PLA) within weight maintenance (WM) and energy deficit (ED) phases.  No 
differences were observed between groups (P > 0.05).        
    
  Participants were admitted to an inpatient unit at PBRC following WM to begin the 28-
day (days 15 - 42) exercise- and diet-induced ED following randomized (1:1 ratio) at the 
beginning of this phase to receive weekly intramuscular injections of 200 mg of testosterone 
enanthate (TEST) or 1 mL of a sesame oil placebo (PLA).  This dose of testosterone 
administered on days 15, 21, 28 and 35 was chosen to maintain normal testosterone 
concentrations during the severe energy deficit (9).  As previously described (10), participants 
performed approximately 3.5 sessions of varied-intensity (40-85% of predetermined VO2peak) 
aerobic-type exercise per day to increase exercise-induced energy expenditure (EIEE) and 




(0.5 x WM TDEE)].  The 55% energy deficit was established by setting energy intake at 45% of 
the elevated TDEE.  The macronutrient distribution of the ED diet was similar to WM and 
dietary intake was not different between groups (Table 5.1).  Exercise modalities used to 
increase EIEE have been reported previously (10) and included elliptical, stationary bike, and 
outdoor/treadmill walking, running, and load carriage (weighted vest ~30% of body mass).  
Exercise intensity was verified biweekly using open circuit indirect calorimetry (ParvoMedics 
TruOne 2400, East Sandy, UT) and adjusted when needed to maintain the prescribed EIEE (10).  
Light calisthenics were also incorporated every 3-4 days but not preformed within 48 hours of 
exercise testing and muscle biopsies.        
Experimental exercise bout and muscle biopsies 
 Percutaneous muscle biopsies of the vastus lateralis were collected before and after a 
steady state aerobic exercise bout on day 14 of WM and following the 28-day ED on day 42.  
The exercise bout included 60 min of cycle ergometry (Lode Excalibur Cycle Ergometer, 
Netherlands) with exercise intensity matched between ED and WM for each participant based on 
power output (124 ± 22 W) and total work performed (448 ± 77 kJ).  Workloads for the 
experimental exercise bouts were determined during the first week of WM using intermittent 
indirect calorimetry assessment of oxygen kinetics throughout a familiarization ride on the cycle 
ergometer.  A total of 3 muscle biopsies were collected from 1 incision on 1 leg per biopsy 
protocol day using a 5 mm Bergstrom needle with manual suction (15) and under local 
anesthesia (1% lidocaine).  The biopsy needle was inserted at different angles to separate 
samples sites by ~ 5 cm and limit excessive trauma or inflammation.  Muscle biopsies were 
collected under fasted, rested conditions [Baseline (Base)] and again after the cycle ergometry 




standardized meal after the 60-min post-exercise biopsy providing 25% of TDEE, 40 g of protein 
from animal sources, and 30% of kcals from fat.  Absolute energy and macronutrient content of 
this meal was not different between groups during WM or ED (Table 5.2).    
 
 
Table 5.2.  Macronutrient composition of the post-exercise meal in TEST 
versus PLA at weight maintenance and energy deficit 
 Testosterone (n = 10) Placebo (n=10) 
 WM ED WM ED 
Absolute intake  
     Energy (kcal)    676 ± 122    390 ± 58     640 ± 101    376 ± 45 
     Carbohydrate (g)      81 ± 22      29 ± 10     75 ± 19      26 ± 10 
     Protein (g)      40 ± 0      40 ± 0       40 ± 0      40 ± 0 
     Fat (g)      23 ± 4      13 ± 1       21 ± 3      13 ± 1 
Values are presented as mean ± SD.  Independent sample t tests were used to compare 
testosterone (TEST) and placebo (PLA) within weight maintenance (WM) and energy 




Transcript levels of select genes linked to skeletal muscle inflammation [interleukin 6 
(IL-6), IL-6 receptor (IL-6R), tumor necrosis factor-α (TNFα), TNFα-receptor (TNFα-R), TNF-
like weak inducer of apoptosis (TWEAK), fibroblast growth factor-inducible 14 (Fn14)], 
myogenesis [MyoD, myogenin, paired box 7 (Pax7), myogenic factor 5 (Myf5)], and protein 
breakdown [muscle atrophy F-box (MAFbx), muscle ring fiber 1 (MuRF1)] were determined 
using commercially available TaqMan® probes (Applied Biosystems, Foster City, CA).  Total 
RNA was extracted from ~15 mg of muscle with TRIzol (ThermoFisher, Waltham, MA) and 
assessed for quality and quantity using a Nanodrop ND-2000 spectrophotometer (NanoDrop, 




using High-Capacity cDNA RT Kits (Applied Biosystems) and a T100TM Thermal Cycler (Bio-
Rad, Hercules, CA).  Samples were run in 10 µL reactions in duplicate using TaqMan® fast 
advanced master mix with a Step One Plus Real-Time PCR system (Applied Biosystems).  Data 
were normalized to the geometric mean of GUSB and TUBB mRNA, and fold changes were 
calculated using the ΔΔCT method (24).  ED data were expressed as a fold change relative to 
WM for TEST and PLA at each time point (i.e., Base, Post, Rec).  One Fn14 value at Base and 
an IL-6 data point at Base, Post, and Rec were considered outliers and removed given their 
values were greater than 3 standard deviations from the mean.            
Intracellular signaling 
 Total protein content of androgen receptor (AR) and the relative abundance and 
phosphorylation state of proteins involved in mammalian target of rapamycin (mTOR)-mediated 
anabolic signaling were determined using standard SDS-PAGE and Western blot analysis.  
Approximately 15 mg of muscle were homogenized in ice-cold lysis buffer with protease and 
phosphatase inhibitors.  Homogenized samples were snap frozen in liquid nitrogen, thawed on 
ice and centrifuged for 15 min at 10,000 g (4°C).  Supernatant (lysate) was subsequently 
collected, and protein concentrations were determined using a 660 nm Protein Assay 
(ThermoScientific, Rockford, IL).  Muscle lysates were solubilized in Laemmli buffer and 
loaded in equal amounts (i.e., 20 µg/lane) into precast Tris-HCl gels (Bio-Rad).  Proteins were 
then separated by SDS-PAGE and transferred to polyvinylidene fluoride membranes (Bio-Rad) 
that were incubated overnight at 4°C with commercially available primary antibodies specific 
total ribosomal protein S6 (rpS6) (Abcam, Cambridge, MA), p-rpS6Ser240/244, total mTOR, p-
mTORSer2448, total p70 ribosomal protein S6 kinase (p70S6K), p-p70S6KSer424/Thr421, and total AR 




peroxidase-conjugated secondary antibody (Cell Signaling Technology) and signals were 
detected using a ChemiDoc XRS system (Bio-Rad) with Image Lab software (Bio-Rad) 
following application of chemiluminescent reagent (Pierce, Rockford, IL).  Heat-shock protein 
90 (HSP90) was used to confirm equal amounts of protein loaded per well.  Phosphorylation 
status was expressed relative to the total amount of each protein and total protein content was 
expressed relative to HSP90.  ED data were shown as a fold change from WM for TEST and 
PLA at each time point (i.e., Base, Post, Rec).    
Muscle fiber cross sectional area  
 A portion of the muscle collected from the WM (d 14) and ED (d 42) Base biopsies was 
used to characterize cross-sectional area (CSA) of Type II fast-twitch and Type I slow-twitch 
myosin heavy chain myofibres.  Methodological details and findings for all 50 participants have 
been reported previously (10).  Type I and Type II CSA data specific to participants selected for 
the current chapter have been summarized as a change from WM to ED.    
Body composition    
 Body composition (total body mass, lean body mass, and fat mass) measured via dual-
energy X-ray absorptiometry (DXA; Lunar iDXA, GE Healthcare, Madison, WI) was a primary 
outcome of the parent study (10), and is reported in this chapter for the involved participants as a 
change from WM to ED.  DXA scans were conducted on days 11 and 39 after an overnight fast 
and morning void using the participant positioning standards reported previously (10).   
Endocrine profile   
Endocrine profiles were analyzed from fasted blood samples collected before the first 
muscle biopsy procedure on days 14 and 42, and have been presented previously for all 50 




analyze blood samples for total testosterone (TT), follicle-stimulating hormone (FSH), estradiol 
(E2), sex-hormone binding globulin (SHBG), luteinizing hormone (LH), and insulin.  Insulin-
like growth factor-1 (IGF-1) was analyzed using an enzyme-linked immunoassay (ALPCO, 
Salem, NH) and Glucose was analyzed on a Beckman DXC 600 Pro (Brea, CA).  Blood was 
sampled between the hours of 06:00 and 09:00 given the diurnal variation of total testosterone in 
young men (25).  Hormone data in the current chapter is presented for the involved participants 
as a change from WM to ED.     
Participant stratification 
 Baseline inflammatory and myogenic gene expression were initially analyzed for all 50 
participants given the previously reported increase in leg lean mass during ED with testosterone 
supplementation (10), and the positive association between changes in leg lean mass and change 
in total testosterone following the 28-day energy deficit (r = .541, p < 0.001).  Given that no 
differences were noted between groups for these parameters (Fig. 5.2), the top (TEST) and 
bottom (PLA) 10 participants with respect to changes in leg lean mass and total testosterone 
were selected for further analyses (Fig. 5.3).  This allowed exclusion of participants whose 
testosterone or leg lean mass did not change during the intervention in an effort to better 
characterize the intracellular signaling and gene expression mediating the hypertrophic effects of 










































Figure 5.2.  Baseline inflammatory and myogenic gene expression for TEST and PLA including all 50 
participants.  Base gene expression at the end of ED was expressed as a fold change relative to WM for 
male participants receiving 200 mg of testosterone enanthate [TEST (□)] or 1 mL of a sesame seed oil 
placebo [PLA (■)] per week during the 28-day ED phase.  Data were normalized to the geometric mean 
of β-actin, and fold changes were calculated using the ΔΔCT method (24).  Unpaired t-tests were used to 
examine differences between TEST and PLA and values are presented as mean ± SD.  No differences 
were observed between groups (P > 0.05)   
 
 


























Figure 5.3. Participant stratification according to leg lean mass and total testosterone.  Change in leg 
lean mass (kg) and total testosterone (ng/dL) were positively associated for all 50 participants (r = 
.541, p < 0.001).  We selected the top (TEST) and bottom (PLA) 10 participants (n=20) with respect to 







Statistical analysis  
 Gene expression and protein abundance data at ED were expressed as a fold change from 
weight maintenance at Base, Post, and Rec.  TEST versus PLA was evaluated at each time point 
using unpaired t-tests.  Unpaired t-tests were also used to analyze body composition and 
endocrine profile data, dietary intake, and macronutrient composition of the post-exercise meal 
in TEST versus PLA.  Associations between Fn14 gene expression, AR total protein content, and 
the change in leg lean mass expressed as ED - WM were explored using stepwise linear 
regression.  Data within the text and figures are presented as mean ± SD.  The α level of 
significance for all statistical tests was two-tailed and set at P < 0.05.  Data were analyzed using 
IBM SPSS Statistics were Windows Version 26 (IBM Corp. Armonk, NY, USA).       
 
 
Results   
 Participants selected for this analysis were not different with respect to age or BMI 
(Table 5.3) as well as dietary intake during WM and ED, and after the experimental exercise 
bout (Table 5.1 and 5.2).  Changes in body composition and endocrine profile in response to the 
28-day ED phase, however, were statistically different between groups (Table 5.4).  The loss of 
total body and leg mass was less for TEST (-0.9 ± 1.0 kg and -0.3 ± 0.7 kg) versus PLA (-5.1 ± 
1.4 kg and -1.8 ± 0.6 kg).  The TEST group also displayed a greater preservation and increase in 
lean body mass (TEST, 3.8 ± 1.2 kg; PLA, -0.9 ± 1.0 kg), leg lean mass (TEST, 1.2 ± 0.7 kg; 
PLA, -0.7 ± 0.4 kg) and trunk lean mass (TEST, 2.4 ± 0.8 kg; PLA, 0.4 ± 0.7 kg).  Testosterone 
versus placebo supplementation during ED in these participants led to a more positive change in 




decrease in FSH and LH from WM.  A greater increase in SHBG, a marker inversely related to 
available testosterone, was also observed for PLA.   
 Muscle TWEAK, TNFα-R, TNFα, IL-6R, IL-6, Myogenin, Pax7, Myf5, and Myf6 gene 
expression were not significantly different between TEST and PLA at any ED time points (Fig 
5.4 B-F, H-K).  In contrast, Fn14 gene expression at Base following ED was lower in TEST 
versus PLA (Fig 5.4 A, P < 0.05).  MAFbx and MuRF1 gene expression at Rec following ED 
was also lower in TEST versus PLA (Fig 5.4 L-M, P < 0.05), while MyoD gene expression was 
greater for TEST at the same time point (Fig 5.4 G, P < 0.05).  AR total protein content was 
greater for TEST versus PLA at the end of ED (Figure 5.5, P < 0.05).  Phosphorylation status 
and relative abundance of mTOR, p70S6K, and rpS6 were not different between groups at any 
time point (Figure 5.6 A-F).        
 Stepwise linear regression analyses showed increased androgen receptor total protein 
content was associated with greater gains in leg lean mass during energy deficit (Fig 5.6 A, r = 
.540, P < 0.05).  A trend for a similar association between increased leg lean mass and decreased 
Fn14 gene expression was also observed (Fig 5.6 B, r = -.455, P = 0.058).  Decreased Fn14 gene 
expression was also associated with increased androgen receptor total protein content (Fig 5.6 C, 
r = -.563, P < 0.05) 
 
Table 5.3.  Participant baseline characteristics in PLA and TEST  
   PLA (n=10)   TEST (n=10) 
Age (y)        22 ± 3           25 ± 6 
Height (cm)      177 ± 7         175 ± 7 
Weight (kg)        80 ± 15           71 ± 10 
BMI (kg/m2)        25 ± 3           23 ± 2 






Table 5.4.  Change in body composition, muscle fiber CSA, and endocrine profile 
with energy deficit 
      ED – WM, Δ  
 TEST  PLA P-value 
Body composition    
Body mass, kg    
     Total       -0.9 ± 1.9*       -5.1 ± 1.4 <0.0001 
     Lean -      3.8 ± 1.2*       -0.9 ± 1.0 <0.0001 
     Fat       -4.7 ± 1.6       -4.1 ± 1.2 .348 
Leg mass, kg    
     Total       -0.3 ± 0.7*       -1.8 ± 0.6 <0.0001 
     Lean -      1.2 ± 0.7*       -0.7 ± 0.4 <0.0001 
     Fat       -1.5 ± 0.4       -1.3 ± 0.3 0.063 
Trunk mass, kg    
     Total       -0.3 ± 1.4*       -2.2 ± 0.9 0.003 
     Lean -      2.4 ± 0.8        0.4 ± 0.7 <0.0001 
     Fat       -2.7 ± 1.1       -2.6 ± 1.0 .798 
    
Muscle fiber CSA    
     Type I, µm2       478 ± 1126       394 ± 1141 .876 
     Type II, µm2      -827 ± 1151    -1059 ± 1161 .710 
    
Endocrine Profile    
     TT, ng/dL    711.9 ± 159.3*   -193.4 ± 77.8 <0.0001 
     FT, ng/dL      19.0 ± 3.7*       -6.0 ± 1.7 <0.0001 
     FSH, mIU/mL       -3.2 ± 1.2*       -0.6 ± 1.0 0.007 
     E2, pg/mL      39.7 ± 17*       -9.1 ± 8.8 <0.0001 
     SHBG, µg/mL        3.7 ± 9.3*      18.3 ± 9.7 0.003 
     LH, mIU/L       -2.8 ± 1.0*       -1.1 ± 1.5 0.009 
     IGF-1, ng/mL     -82.7 ± 85.6   -120.8 ± 77.3 .310 
     Glucose, mg/dL     -10.2 ± 8.8       -8.5 ± 14.7 .757 
     Insulin, µIU/mL       -7.4 ± 8.5       -7.0 ± 11.3 .925 
     Cortisol, µg/dL        4.7 ± 4.3        6.0  ± 4.5 .494 
Values are mean ± SD.  Data were expressed as energy deficit (ED) minus weight 
maintenance (WM) and differences between TEST and PLA were analyzed using unpaired t 
tests. *Indicates group differences (P < 0.05)   CSA, cross-sectional area; TT, total 
testosterone; FT, free testosterone; FSH, follicle stimulating hormone; E2, estradiol; SHBG, 
sex-hormone binding globulin; LH, luteinizing hormone; IGF-1, insulin-like growth factor-1 
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Figure 5.4.  Skeletal muscle inflammatory, myogenic, and proteolytic gene expression after energy deficit.  ED data were 
expressed as fold change relative to WM at baseline (Base), 1 h after 60 min of cycle ergometry (Post), and an additional 5 hours 
into recovery (Rec) from exercise after a protein-containing meal for male participants receiving 200 mg testosterone enanthate 
[TEST (□)] or 1 mL of a sesame oil placebo [PLA (■)] weekly during the 28-day ED phase.  Data were normalized to the 
geometric mean of GUSB and TUBB, and fold changes were calculated using the ΔΔCT method.  Differences between TEST and 
PLA at each time point were examined using unpaired t-tests.  Values are presented as mean ± SD.  *TEST different than PLA, P 
< 0.05.  Fn14, fibroblast growth factor-inducible 14; TWEAK, tumor necrosis factor-like weak inducer of apoptosis; TNFα, 
tumor necrosis factor-α, TNFα-R, tumor necrosis factor-α-receptor; IL-6, interleukin 6; IL-6R, interleukin 6 receptor; Pax7, 
























Figure 5.5.  Androgen receptor total protein content after energy deficit.  Base total protein content of AR at the 
end of ED was expressed as a fold change relative to WM for male participants receiving 200 mg of testosterone 
enanthate [TEST (□)] or 1 mL of a sesame seed oil placebo [PLA (■)] per week during the 28-day ED phase.  
Total protein content was normalized to HSP90 and values are presented as mean ± SD.  *TEST different than 
PLA, P < 0.05.     
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Figure 5.6.  mTOR-mediated anabolic signaling after energy deficit.  Abundance of p-mTORSer2448 (A), p-
p70S6KSer424/Thr421 (B), p-rpS6Ser240/244 (C), total mTOR (D), total p70S6K, and total rpS6 (E) following ED 
was expressed as fold change relative to WM at baseline (Base), 1 h after 60 min of cycle ergometry (Post), 
and an additional 5 hours into recovery (Rec) from exercise after a protein-containing meal for participants 
receiving 200 mg of testosterone enanthate [TEST (□)] or 1 mL of a sesame oil placebo [PLA (■)] weekly 
during the 28-day ED phase.  Phosphorylation status was expressed relative to the total amount of each 
protein and total protein content was expressed relative to HSP90.  Values are presented as mean ± SD and no 



















































































) r = -.563
p = 0.015
 
Figure 5.7.  Associations between the change in Fn14 gene expression, AR total protein 
content, and leg lean mass with energy deficit.  Leg lean mass measured via DXA is 
presented as WM – ED (Δ).  Fn14 gene expression was normalized to the geometric mean of 
GUSB and TUBB, and fold change was calculated using the ΔΔCT method (24).  AR total 
protein content was normalized to HSP90.  Fn14 gene expression and AR total protein 





Discussion     
 The current study examined mTOR pathway signaling, ubiquitin-mediated proteolysis, 
and myogenic regulatory factor expression following a 28-day diet- and exercise-induced energy 
deficit (~55% deficit) with supplemental testosterone (200 mg testosterone enanthate/wk) or a 
placebo.  The primary observation of this investigation is that testosterone supplementation 
during energy deficit attenuated markers of muscle protein breakdown and increased MyoD gene 
expression at Rec, while mTOR-mediated anabolic signaling was not different between groups at 
any time point.  Base expression of AR and Fn14, two potential upstream regulators of 
myogenesis and ubiquitin-mediated proteolysis, were different in TEST versus PLA after ED, 
and were also associated with changes in leg lean mass.  These novel findings suggest that 
exogenous testosterone administration during a severe diet- and exercise-induced energy deficit 
attenuates proteolysis and enhances myogenesis after exercise and feeding, possibly via AR and 
Fn14 signaling.  This may account, in part, for the increase in leg lean mass observed in the 
TEST group during ED. 
 Expression of the myogenic regulatory factor MyoD was greater at Rec in TEST versus 
PLA after the ED phase, indicating a heightened myogenic response following exercise in these 
individuals.  This is consistent with in vitro work (13, 17) and humans studies (12) 
demonstrating enhanced myogenesis with the administration of exogenous testosterone.  The 
activation, proliferation, and differentiation of satellite cells (i.e., myogenesis) is critical 
following exercise to repair and replace damaged muscle fibers, and ultimately maintain muscle 
mass and function (26, 27). Increased fusion of activated satellite cells to existing muscle fibers 
may also contribute to greater muscle volume (16).  This suggests that the observed testosterone-




maintenance or increase of muscle mass during energy deficit.  The decreased expression of 
muscle protein breakdown markers (i.e., MAFbx and MuRF1) in TEST versus PLA at Rec, 
indicates testosterone supplementation may also protect muscle mass during energy deficit by 
attenuating proteolysis after exercise and feeding. 
Interestingly, we observed no differences between groups in mTOR signaling, suggesting 
a limited role of protein synthetic pathways in mediating the hypertrophic effect of testosterone 
supplementation during energy deficit.  This was surprising given literature reporting increased 
rates of protein synthesis under fasted conditions following exogenous testosterone 
administration in humans (28, 29).  While this discrepancy may be due to differences in energy 
status (i.e., energy balance vs. energy deficit), the role of mTOR signaling in regulating protein 
synthesis during basal, non-stimulated conditions is unclear (29).  It is possible that fasted rates 
of synthesis were increased similar to previous studies without concomitant changes in mTOR 
pathway activity.  Future work should employ dynamic measures of protein synthesis (i.e., stable 
isotope methodology) to further understand the effect of testosterone on muscle protein synthesis 
during energy deficit.   
The lack of changes in mTOR signaling in the TEST group was unexpected given 
mechanistic studies implicating the mTOR pathway in testosterone-induced increases in myotube 
hypertrophy (14, 31).  However, this in vitro work may not accurately reflect the fasted 
conditions under which testosterone-induced increases in protein synthesis have been observed 
in humans.  Rossetti et al. (11) have suggested that future studies should employ periods of 
fasting in animal models and serum or nutrient deprivation prior to harvesting cultured cells to 
better understand molecular signaling underlying the androgen-mediated increase in protein 




 Androgen receptors (AR) may mediate some of the effects of supplemental testosterone 
during energy deficit.  We observed greater AR total protein content at the end of the ED phase 
in TEST versus PLA.  Satellite cells are the predominant site of AR expression in human skeletal 
muscle (32) suggesting the observed increase in androgen binding sites may be linked to the 
regulation of myogenic activity.  Androgens that cross the cell membrane bind the AR, and the 
resulting complex alters transcriptional activity by interacting with androgen response elements 
(ARE) of target genes.  Lee et al. (18) have reported a relationship between androgen-AR 
signaling and enhanced myogenin expression and myoblast differentiation following testosterone 
administration in C2C12 cells.  Intact AR was also necessary for the increase in mRNA and 
protein levels of MyoD and myosin heavy chain II (MHC) in mouse mesenchymal C3H 10T1/2 
cells incubated with testosterone, indicating testosterone can recruit mesenchymal pluripotent 
stem cells into the myogenic lineage in an AR-dependent manner (13).  These data suggest 
testosterone-mediated changes in muscle AR content may be linked to the observed increase in 
post-exercise myogenic signaling (i.e., MyoD expression) in TEST versus PLA. 
 Observed changes in MyoD and markers of muscle protein breakdown in TEST versus 
PLA may be linked to upstream activity of the TWEAK receptor Fn14, a potent regulator a 
skeletal muscle mass.  We observed lower Fn14 expression in TEST versus PLA at Base 
following the ED phase.  Levels of Fn14 are generally low in healthy tissues and therefore the 
induction of Fn14 expression is tied to TWEAK/Fn14 pathway activity (33).  Heightened 
activation of this pathway in TWEAK-treated myoblasts has been shown to impair myogenesis 
by decreasing gene expression and protein levels of MyoD and myogenin (34, 35).  TWEAK-
mediated activation of Fn14 signaling in cultured myotubes has also been shown to increase 




observed in PLA versus TEST in this study may be linked to the lower MyoD gene expression 
and greater levels of MAFbx and MuRF1 in these individuals.  Interestingly, lower Fn14 
expression in TEST versus PLA may be regulated by AR activity.  Yin et al (37) reported an 
inverse relationship between Fn14 expression and AR signaling output (i.e., mRNA signature of 
AR target genes) in a microarray dataset composed of 131 primary and 19 metastatic prostate 
cancer samples.  Predicting androgen response elements (ARE) in Fn14 promoter regions and 
subsequent analyses revealed that AR binding to the Fn14 enhancer decreased its expression 
(37).  While it is not completely clear if these findings translate to muscle cells, the inverse 
association between Fn14 and AR observed in the current study support a similar mechanism of 
action human skeletal muscle.  Therefore it is possible that AR-induced attenuation of Fn14 
expression may mediate the increase in MyoD and attenuation of MAFbx and MuRF1 with 
testosterone supplementation during ED.  The idea that AR and Fn14 regulate myogenic and 
proteolytic pathways to mediate the anabolic effect of exogenous testosterone during energy 
deficit is supported by the association between AR and change in leg lean mass (r = .540, p = 
0.02) as well as Fn14 and change in leg lean mass (r= -.455, p = 0.058). 
The findings of this study should be interpreted in the context of a few limitations.  While 
mTOR-mediated anabolic signaling was not different between groups, we cannot confirm 
whether rates of muscle protein synthesis (MPS) were also unaffected by the testosterone 
intervention given the lack of stable-isotope derived measures of synthetic rates.  Future work is 
needed to further elucidate the effect of testosterone supplementation on MPS during energy 
deficit.  We acknowledge that our selection of the top (TEST) and bottom (PLA) 10 participants 
from the parent study with respect to changes in leg lean mass and total testosterone may also be 




testosterone induced by energy deficit in the placebo group was less than anticipated (10).  In 
fact, there were several individuals whose lean mass or total testosterone did not change 
following the 28-day energy deficit.  Nonetheless, stratifying participants based on the change in 
total testosterone and leg lean mass allowed us to exclude these individuals to better characterize 
intracellular signaling and gene expression mediating the hypertrophic effect of supplemental 
testosterone during energy deficit.    
 The current study presents novel information about the molecular impacts of 
supplemental testosterone during a severe diet- and exercise-induced energy deficit.  We report 
that testosterone supplementation during energy deficit upregulates myogenesis and attenuates 
ubiquitin proteasome-mediated proteolysis after exercise and feeding.  mTOR pathway 
activation was not different between groups suggesting a negligible role of this signaling 
pathway in mediating the hypertrophic effect of testosterone supplementation during energy 
deficit.  An increase in AR total protein content and decrease in Fn14 gene expression in TEST 
following ED, and the association of these markers with change in leg lean mass suggests 
signaling through these pathways mediates the effect of testosterone on downstream myogenic 
and proteolytic activity.  Whether these findings can be effectively translated into androgen-
related therapies for mitigating muscle losses during situations of extreme operational stress or 
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Summary and Recommendations 
Muscle atrophy occurs with reduced loading and neural activation of muscle after 
musculoskeletal injury (i.e., disuse atrophy), and during energy deficit resulting from inadequate 
caloric intake.  Manipulating dietary protein or administering exogenous testosterone under these 
muscle wasting conditions may protect muscle mass and/or function by increasing muscle 
protein synthesis (MPS), attenuating muscle protein breakdown (MPS), and enhancing muscle 
regenerative capacity either directly or through upstream modulation of inflammatory signaling.  
Multiple investigations were conducted to assess the influence of dietary protein and testosterone 
supplementation on the regulation of muscle mass with disuse after injury and during energy 
deficit.   
Results from Study 1 suggest higher protein intakes before ACL reconstruction surgery 
do not influence perioperative markers of inflammation and myogenesis.  This was likely limited 
by the small sample size (n=5), however, given the large effect sizes (d > 1.0) and post hoc 
power analyses for several parameters that revealed a sample size of 10 to 18 subjects would be 
needed for group differences to reach statistical significance.  Future investigations with larger 
sample sizes are needed to further elucidate whether manipulating dietary protein intake can 
influence inflammation and muscle regenerative capacity assessed at the time of surgery.  
Interestingly, a secondary analysis of a subset of subjects revealed several markers of 
inflammation and myogenesis at the time of surgery were associated with postoperative thigh 
circumference and quadriceps strength during postoperative rehabilitation.  While we 
acknowledge that the small sample size (n=4) and correlative nature of this analysis are 




muscle inflammation and regenerative capacity are associated with postoperative muscle 
recovery outcomes.   
The case study included in Chapter 4 provides important insight into the role of dietary 
protein intake in regulating skeletal muscle mass during disuse following musculoskeletal injury.  
The patient’s gains in injured leg thigh circumference following ACL reconstruction suggests 
that consuming ~2.0 g protein·kg-1·d-1 may have benefited recovery by attenuating disuse 
atrophy and potentiating muscle hypertrophy during postoperative rehabilitation.  The 
progressive increase in thigh circumference and quadriceps strength in the non-injured leg also 
indicates that physical rehabilitation is analogous to resistance exercise in promoting gains in 
muscle mass and strength, particularly when combined with a higher protein diet.    Observations 
for this case study must be cautiously interpreted given the use of thigh circumference to 
estimate changes in muscle mass, as this measurement cannot differentiate the individual 
contributions of muscle mass and subcutaneous fat to total thigh size.  Future work with larger 
populations is warranted to further understand how protein intake at the higher end of clinical 
recommendations protects muscle mass post-injury, and should use DXA, MRI, or CT scans to 
evaluate changes in muscle volume or cross sectional area.   
Study 2 presents novel information about the molecular impacts of supplemental 
testosterone during a severe diet- and exercise-induced energy deficit.  Findings suggest that 
exogenous testosterone administration during energy deficit attenuates proteolytic gene 
expression and enhances myogenesis after exercise and feeding.  It also appears that AR-induced 
attenuation of Fn14 expression may regulate the observed changes in myogenesis and proteolysis 
to mediate the anabolic effect of exogenous testosterone during energy deficit.  As discussed, 




given that there were several participants whose leg lean mass or total testosterone did not 
change during the energy deficit.  While this may be considered a limitation, this method of 
analysis allowed us to exclude these individuals to better characterize intracellular signaling 
mediating the hypertrophic effect of supplemental testosterone during energy deficit.  Future 
work inducing greater changes in testosterone status and lean mass during energy deficit by 
administering lower doses of testosterone or implementing greater stressors is needed to further 
elucidate the effects of testosterone supplementation on intracellular signaling regulating muscle 
mass during energy deficit.       
In total, findings from Study 1 and Study 2 indicate integration of intramuscular 
inflammation, dietary protein intake, and testosterone-mediated intracellular signaling in the 
regulation of muscle mass during conditions of muscle wasting.  This work is important in 
translating both protein-based diet interventions and supplemental testosterone therapies to the 
recovery from musculoskeletal injury and situations of extreme operational stress, respectively, 












Orthopedic Associates of Hartford 
Return-to-Sport after ACL Reconstruction Protocol 
 
* This protocol is a time and criterion-based protocol, with a goal of maximizing healing and 
strength recovery, while minimizing risk of re-injury, so the athlete can return, as quickly and 
safely as possible, to athletic activities at the pace that is specific for each individual.  
 
Immediately Post-Operative Phase:  
(Week 1, approx. days 1-7 post-operatively) 
 
Goals of this phase are: 
- Restore full passive knee extension, and gradually  knee flexion to 90 
- Diminish joint swelling and pain 
- Restore patellar mobility 
- Re-establish quadriceps control- active quadriceps contraction with superior patellar glide 
- Improve ambulation to FWB/  assistive device use 
 
Physical Therapy Interventions: Perform/increase number and duration of exercises as 
tolerated 
- Gait Training: 
o Patient is WBAT in full locked extension brace with bilateral crutches, patient is 
provided instruction, demonstration and given verbal and tactile cues as 
appropriate to ensure the crutches are safe and are of the correct height for the 
should and hand grips 
- Exercises: 
o Ankle Pumps to  swelling/edema 
o Ankle resistance band open chain exercises- all 4 directions 
o Patellar mobilization in all directions 
o Quadriceps and Gluteal Isometric Setting 
o Hamstring Stretches- hamstring re-lengthening- Gentle if H/S graft used 
o Straight Leg Raises (flexion, abduction, adduction) 
o Gastrocnemius Stretching + Manual Release for re-lengthening + Knee / 
o Active and Passive Knee Flexion exercises to tolerance, not pushed- (to 90 by 
days 5-7) 
o Wall Heel Slides (supine with foot on wall/window) for increasing knee flexion, 
or seated AAROM  
o Gentle overpressure into full extension (PT or pt. actively) 
o Weight Bearing: weight shifts in full extension brace 
o Standing Hamstring Concentric & Eccentric- 9040 (no weight) 
- NMES: Russian E-stim 2,500Hz with other appropriate settings): 
o  Can and should be used, especially if contraction deficit is present, during active 




- CP with full Extension, +/or Kinesiology Tape (basket-weave technique), dry needling 
technique, (control swelling/edema) 
- Home Exercises Program- See HEP for Immediately Post-op Phase 
 
 
Early Post-Operative Phase:  
(~ 2 – 4 weeks Post-Op) 
 
Criteria for entering this phase is: 
1- Quadriceps voluntary initiation with quad set and SLR  
2- Full passive knee extension 
3- Knee A + PROM of 0-90, with good patellar mobility 
4- Minimal joint effusion 
5- Independent ambulation 
 
Goals of this phase are: 
- To maintain full passive and active knee extension 
- To gradually increase knee flexion to 110-120 
- To diminish swelling and pain 
- Increase muscular training 
- Restore proprioception 
- Maintain patellar mobility 
- Use a semi-recumbent cycle or NUSTEP without difficulty 
- Perform a SLR with no extension lag 
- Reciprocal stair climbing 
- KOS-ADL Score of 65% 
 
Physical Therapy Interventions:  
- Gait Training: WBAT, with a goal of discontinuing use of crutches by day 8-14 post-
op- continue locked brace until voluntary quad control is demonstrated, *May be subject 
to change by MD 
- Exercises: (continue/progress all exercises from previous phase) 
o Continue NMES with quadriceps exercises, if needed 
▪ ~ 4 weeks: Quadriceps isometrics multiple angles (90°, 70°, 50°)  
o SLR in all 4 planes- Hip Abd performed with ~10°-15° of Hip Extension, possible 
progression- 1# weight (*Proximal loading above knee joint)  
o ~ 4 weeks: OKC –Knee Extension 90 to 40, with or without NMES 
o Mini Squats 0-30 DL (BW only) Progress to unstable surface such as tilt board 
(Med./Lat. & Ant./Post.) or foam with 3-5 second holds *Forward trunk tilt- 
recruit H/S & unload ACL, Wall Squats to 40 
o Overpressure into Full Knee Extension, Prone Knee Hangs if it is lacking  
o Hamstring Curls (* Only for B-T-B Graft)- ~8 weeks for H/S Graft 
o PROM 0 to 110-120 
o Weight Shifts- Medial/Lateral & Diagonal Patterns, Balance Weight Shifting- 




o Forward & Lateral Mini Lunges (30°-40° of flexion)- if patient has good 
quadriceps control  
o Step-Ups (pain free range)- Front & Lateral- * Low Step initially 
o Lateral Step Over: Cones, Hurdles- *Instruct to raise knee to level of hip 
o DL Leg Press- *Sub-Maximal 
o Stationary cycle (if ROM permits)/ rocking on LE cycle (not forced) 
- Manual Treatments: 
o Patellar Mobilization (If flexion is limited), Scar Mobs, (If skin is healed) 
o Continue to control swelling: Ice, elevation if needed 
 
 
Intermediate Post-Operative Phase:  
(~4-8 weeks Post-Op) 
 
Criteria for entering this phase: 
1- P & AROM knee flexion to  110 
2- Quadriceps & Hamstring strength to >60% of non-injured leg (dynamometry) 
3- Minimal to no effusion  
4- No joint line or patellofemoral pain 
5- Mild laxity on clinical examination, or +1 mm or less with the KT-2000 test 
a. Week 4  & 6: KT-2000 test at 20 & 30 lbs anterior and posterior 
 
Goals of this phase are: 
- Quadriceps strength to ≥75% of the non-injured leg, H/S ≥75% non-injured leg 
- Restore knee ROM to 0-125, or knee ROM to within 10-15 of non-injured leg 
- Improve lower extremity strength 
- Enhance proprioception, balance, and neuromuscular control 
- Improve muscular endurance 
- Restore limb confidence and function 
- KOS-ADL score or >75% 
- Get an Post-Op score for IKDC or KOOS (age appropriate version) 
 
Physical Therapy Interventions:  
- Gait Training: Unlocked brace, discontinued use if sufficient quad strength is present. 
Retrain with normal walking gait pattern 
- Exercises: (Continue/progress all from previous phases as tol./as needed) 
o OKC Knee extensions: 90-40 
o Front & Lateral step down exercise 
o Heel Raises (raising up onto toes) 
o Progress lateral stepping exercise 
o Mini Squats with forward trunk tilt (to decrease ACL strain + recruit H/S)- in 
Patient’s ROM and Tolerance, not lower than 40°-50° of knee flexion 
o Perturbation Training – DL-> progress to →SL Balance when appropriate- Can 
also use uneven surfaces and external perturbations to progress (DL & SL)- Tilt 




toss & catch/reaching (UE & LE), external tapping on hips and trunk on any 
surface- *With knee slightly flexed 
o Eccentric Exercises: (for H/S & Quad)- Decline Squat, DL+SL Squat, etc.   
o Pool Exercises if available: forward & backward walk/run (*forward at week 
≥6), hip & leg exercises- slow speeds of mvmt. (Graft protection) 
o Begin testing/training for proprioception on the Biodex® Stability System (or 
other system)- *if available, or: BESS Test, Functional Reach Test, Tandem 
Walking tests- See attached sheets 
o Progress Stationary Cycle and Walking- min of 10 minutes, increasing 10min/wk 
(walk) 
o Core Stabilization/Strengthening- Bridging (Progress with Band: Abd→ unstable 
surface→ hamstring curl w/ball), SL Bridge (knee /, Valslide®) 
- Manual Treatments: 
o Continue patellar and scar mobilization if needed 
o Tibiofemoral mobilization with rotation for ROM if needed 
 
 
Late Post-Operative Phase:  
(~8-12 weeks Post-OP) 
 
Criteria for entering this phase: 
1- Active knee ROM 0- 125 
2- Quadriceps Strength & Girth 75% of non-injured leg (dynamometry & tape measure), 
Hamstring Strength ≥75% of non-injured leg (dynamometry) 
 
Goals for this phase: 
- Restore full knee ROM 
- Continue to improve lower extremity strength, balance, proprioception, neuromuscular 
control, muscular endurance 
- Knee effusion to trace or less 
- Quadriceps strength to >80 %, Hamstring Strength >80% of the non-injured leg 
- Normal gait pattern 
- Minimal laxity on clinical exam, or 2mm or less on the KT-2000 test 
- Get a baseline FMS® and Y-Balance™ score at ≥8 weeks post-op- when appropriate- 
Begin with the SFMA (no pain- can proceed to other tests) 
- Patient is tested with the Landing Error Scoring System (LESS): See Attached Sheets: - 
Test at Patient’s individual max vertical jump height, not standard measure on the 
LESS- may be too high or too low for accurate individual jump assessment score, no 
sooner than 10 weeks post-op 
o Excellent Score is </= 4 
o Good Score is >4 and </=5 
o Moderate Score is >5 and </=6 
o Poor Score is >6 
- Perform hop testing at no sooner than 10 weeks post-op: See Attached Sheets  
o 2 practice trials on each leg, then 2 timed or measured trials an each leg; measure 




o 1- Single-leg hop for distance 
o 2- Triple hop for distance 
o 3- Single-Leg Crossover triple hop 
o 4- 6-Metered timed hop  
Physical Therapy Interventions:  
- Exercises: (Continue/progress all exercises from previous phases as tolerance/as 
needed) 
o Progress exercises in intensity & duration, Advance core stab. exercises 
o Continue Perturbation Training- Internal & External Cues 
o Dynamic/Plyometric Leg Press (Begin no sooner than 8 Weeks- To learn 
technique and control ground reaction forces, “land softly on toes with knees 
slightly flexed” for dissipation of force and to avoid hyperextension) 
o Progress lateral stepping and lateral step-down exercises with resistance bands on 
the distal femur creating a medial pull (bilateral with stepping, SL with lateral 
step-down) 
o Begin walk→run protocol, toward the end of phase, when patient is able to 
perform a controlled single leg squat (injured and non-injured legs) to 60° of knee 
flexion- see attached protocol 
o Continue Eccentric Training: (See sheet) 
 
 
Early Activity Phase:  
(~12-16 weeks Post-Op) 
 
Criteria for entering this Phase: 
1- Full knee AROM  
2- Quadriceps Strength & Girth >80% of the non-injured leg, knee flexor-extensor ratio of 
70% to 75%, Hamstring Strength >80% of the non-injured leg (Dynamometer) 
3- No pain or effusion 
4- No laxity/instability on clinical exam, or KT-2000 test of 2mm or less compared to the 
non-injured side 
5- Hop Tests (80% of non-injured leg) 
6- IKDC (use for concomitant injuries)- score of 80% or higher, or the KOOS (use with 
ACL alone) score of 80 
 
Goals for this phase: 
- Normalize lower extremity strength (<15% difference Left to Right) 
- Increase muscle power and endurance, & begin selected skill drills 
- Maintain/Gain Hamstring & Quadriceps Strength and Girth of 80% or greater 
- Hop Tests to > 85% of the non-injured leg 
- Continue to improve neuromuscular control 
- KOS-sports score of > 70% 
- A score of 14/21 on the FMS® Assessment Screen, with No 0/3= pain on any of the 7 
fundamental movement patterns 
- No statistical asymmetries and on the Y-Balance Assessment™ 





Physical Therapy Interventions: 
- Exercises: (Continue/progress exercises from previous phases as tol./need.) 
o Agility exercises- side shuffling, cariocas, zigzags- when appropriate and 
cleared by MD 
o Advanced Core & Hip Stab. exercises: Resisted Clam, Quadruped Reach 
w/Resistance, Lateral Squat Stepping, Side+ Prone Planks w/LE Lift, etc. 
o Continue/Progress Walk-to-Run Protocol 
o Begin Plyometric Training Protocol- when appropriate- landing screening, Hop 
Tests, and no increase in pt’s symptoms- See attached sheets 
o CKC exercises may be progressed to 75-90 of flexion 
o Continue Eccentric exercises: For all LE muscles-ex. Step-Down exercises 
Functional Assessments: 
- FMS® and Y-Balance Assessment™ at beginning and end of this phase 
- Repeat the 4 Hop Tests from the previous Phase at beginning and end of phase 
Core Testing: 
- Segmental Multifidus Test 
- Trunk Curl Up Test 
- Double-Leg Lowering Test 
- Side Bridge Test 
- Prone Bridge Test 
- Supine Single-Leg Bridge Test 
- Extensor Endurance Test 
 
 
Return to Activity Phase:  
 
Criteria for entering this Phase: 
1- Full ROM 
2- A score of 14/21 on the FMS® Assessment Screen, with No 0/3= pain on any of 
the 7 fundamental movement patterns 
3- No statistical asymmetries and on the Y-Balance Assessment™ 
4- Hop Tests (90% or higher compared to non-injured leg) 
5- Limb Symmetry Index (LSI) of 90% or greater on hop tests 
6- IKDC Score  85%, or the KOOS score of 85 
7- KOS-Sports Score 90% or greater 
8- Cincinnati Knee Rating System score of 290 points or higher 
9- No change in knee laxity (clinical exam or  </=2mm on KT 2000 test) 
10- Isokinetic testing: (if available) 
i. Quadriceps (80% or greater) compared to non-injured leg 
ii. Hamstring (100%-110%) compared to non-injured leg 
iii. Hamstring-Quadriceps Ratio (70% or greater) 
 
Goals or this Phase: 




- Normalize neuromuscular control 
- Progress to skill training 
- Gradually return to sport specific training 
Physical Therapy Interventions: 
- Exercises: 
o Continue strengthening exercises 
o Continue/Advance core training exercises 
o Continue Neuromuscular control exercises 
o Continue plyometric exercises 
o Progress running program 
o Begin agility and skill training exercises: 
▪ Continue cariocas, zigzags, side-shuffling 
▪ Begin sudden start and stops, figure-8’s, 45 and 90 cutting drills, box 
jumps (progressing & varying heights up to 20cm) 
Functional Assessment: 
- Repeat 4 previous hop tests, plus Hop-to-Stop test- at the end of this phase 







Standardized Physical Rehabilitation Exercise Protocol 
 
Initial Post-op Phase (~1 week Post-Op) 
- PROM Knee 0°- 90° (as close to full extension as you can get the patient) 
- Manual Techniques: tissue flexibility,  swelling, ROM, Patellar Mobility,  Pain 
- Gait Training: with Bilateral Crutches in Locked Extension Brace 
- Exercises: 
o Ankle Pumps 
o Ankle Resistance Band Exercises- All 4 Directions 
o Quadriceps and Gluteal Set Exercises 
o SLR: Abduction, Flexion with Brace 
o Calf Stretches with strap 
o Heel/Wall Slides for knee flexion 
o Weight Shifting in Locked Extension Brace 
 
Early Post-Op Phase (~ 2-4 weeks Post-Op) 
- Continue Manual Techniques as needed, add scar mobilization when incision is healed 
- ROM: 0°-120° 
- Gait Training: WBAT D/C Crutches as tol. (MD Decision, ~8-14 days Post-Op) 
- Exercises: 
o SLR: all 4 Planes (Hip Abduction performed with 10°-15 of hip extension) 
o NMES: (~4 weeks Post-Op) 
▪ OKC Knee Extension: (90°-40°)- * No Weight 
▪ Quadriceps Isometrics: (90° and 60°)- *No Weight 
o Mini Squats: DL (0°-30°) Body Weight Only- with forward trunk tilt (to  ACL 
load) 
o Front and Lateral Step-Ups: (low Step- in pain-free range) 
o DL Press (*Sub-Maximal) 
o Lateral Step Overs: (Instruct patient to raise knee to the level of the hip) 
o Stationary Cycle (Not Forced): Rocking back and forth if full revolution cannot 
be achieved 
o * See full Protocol for Phase Progress Criteria 
 
Intermediate Post-Op Phase (~4-8 weeks Post-Op) 
- Continue Manual Treatments as needed 
- ROM: 0°-125°, (or within 10°-15° of uninjured knee) 
- Gait Training: Brace D/C’d by MD during this phase- Normalize the Gait Pattern 
- Exercises: 




o Heel Raises (DL & SL) 
o Mini Squats with Forward Trunk Tilt (no lower than 45°-50° Knee Flexion) 
o Front and Lateral Step Downs 
o Continue Quadriceps and Hamstring Stretches 
o Side-Lying Clam Exercise (progress with resistance band as tol.) 
o Continue SLR Hip Abduction (with ~10°-15° Hip Extension) 
o Standing Hamstring Curls: (~8 weeks Post-Op)- Concentric and Eccentric 
o Bridges: (~8 weeks Post-Op) DL 
o DL & SL Leg Press: ( ’ing resistance) 
▪ Progress from DL to SL as tolerated 
o * See full Protocol for Phase Progress Criteria 
 
Late Post-Op Phase (~8-12 weeks Post-Op) 
- Continue Manual Treatments as needed 
- ROM: Should be equal to uninjured knee 
- Exercises: 
o DL + SL Squats: (Internal and External Cues) 
▪ Tape vertically on knees and floor about shoulder width apart, Patient 
must keep the tape pieces lined up 
▪ Resistance band:  
• To Assist Equal Weight-Bearing- Band at waist tied off laterally 
on side of injury to cue to load injured LE 
• Knee Valgus- Band just about injured knee pulling medially, so 
patient has to resists going into Valgus 
• Trunk Rotation- Band around ipsilateral shoulder to injury, then 
it goes around the back and around the contralateral side waist and 
is tied off anterior to the patient. As patient goes into the squat they 
must resist trunk rotation. 
o SL Anterior Reaches: (with or without Valslide®) 
o Progress Forward and Lateral Stepping Exercises: (  step height) 
o Bridges with Knee Extension: (DL/SL), and with ball H/S curl 
o Anterior and Lateral Lunges: (tolerable range) with Knee Valgus/Varus control 
 
o Dynamic Stretches: 
▪ Toe + Heel Walks, Knee Hugs, Butt Kicks, Toe Swipes, Monster Walks, 
Fig-4 Squat walk 
o Perturbation Training: (~10 Weeks Post-Op)- SLS on Foam/Wobble 
board/Balance Disc 
▪ Progress to include ball toss/catch, Bird Dips/Dead Lifts (0#/ light weight 
initially) 






Early Activity Phase (~12-16 weeks Post-Op) 
- Exercises: 
o Continue Bridge Exercises 
o Progress Clam Exercise: with Resistance Band 
o Continue DL + SL Squats:  
▪ Progress Internal (Surface, Tape) and External (Bands, Ball Toss, Manual 
Touches) Perturbations 
o Lateral and Forward Squat Walks with Resistance Band: 
o Quadruped UE+ LE Reaches: with Resistance Band 
o Side and Prone Planks: (10 Seconds holds) 
▪ Progress with Leg Raises 
o Dynamic Stretches: 
▪ All Previous Stretches, plus: Ankle Grab 1-hand floor touch, lift added to 
Fig-4 Squat, High Knee Jog, Inverted Hamstring Stretch, Anterior Lunge 
with Upper Body Extension, Lateral Lunge, and Inchworm Stretch 
o Dynamic/Plyo Leg Press/Jumps 
o Begin Walk-To-Run Protocol: Patient Must be able to demonstrate Controlled 
SL Squats to 60° of Knee flexion 
o * See full Protocol for Phase Progress Criteria 
  
 
